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Abstract
The Lens Epithelial Derived Growth Factor p75 (LEDGF/p75) is a chromatin bound
protein whose cellular function is not yet clearly known. A role in transcriptional regulation had
been previously proposed based on its interaction with the basal transcriptional machinery and
on its effects on the expression of genes involved in the cellular response to environmental
stresses. To further elucidate the function of LEDGF/p75, we conducted a global and unbiased
evaluation of the role of this protein in gene expression. To that aim, we performed a microarray
analysis of cellular gene expression in cells that are severely depleted of LEDGF/p75. To
minimize cell type-specific observations, we used three different LEDGF/p75 deficient human
cell lines: embryonic kidney epithelial cells (HEK293) and two different lines of CD4+ T cells
(SupT1 and Jurkat). By taking the intersection of the three data sets, using a fold-change of
greater than two and a student t-test confidence value of 90% we have identified a group of
genes whose expression is dysregulated in at least two of the cell types tested.
The potential role of LEDGF/p75 in transcriptional regulation of responsive genes has
been described as operating at the level of their promoters as a general co-activator, connecting
members of the basal transcriptional apparatus to DNA sequence specific transcriptional
activators. However, the observation that LEDGF/p75 is bound to sites within the chromatin
across the genome suggests that this protein is also present inside actively transcribed genes. In
correlation with this observation, LEDGF/p75 has been demonstrated to promote integration of
cDNA copies of the HIV-1 genome within actively transcribed genes. This localization of
LEDGF/p75 inside actively transcribed genes suggests a possible role of LEDGF/p75 in
transcriptional elongation. To further investigate whether LEDGF/p75 has a role in
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transcriptional elongation, we performed a transcriptional profile analysis of genes we previously
identified as dysregulated in SupT1 and HEK293 cells. We used chromatin immunoprecipitation
and quantitative real time PCR analysis to demonstrate that LEDGF/p75 is located on the
intragenic regions of these genes as well as their promoters. LEDGF/p75 occupancy on these
genomic locations correlated with the gene transcriptional activity. We also demonstrate that
LEDGF/p75 coimmunoprecipitates with CDK9 and the FACT complex, two separate
components of the transcriptional elongation complex, and corroborated this association by
quantitative confocal colocalization.
In order to understand the mechanism of LEDGF/p75 on transcriptional regulation at the
promoter level, we studied the effect of LEDGF/p75 on the shared bi-directional promoter of the
LEDGF/p75-regulated genes DTX3L and PARP9. Our data indicate that LEDGF/p75 negatively
regulates the expression of this promoter. Two known motifs within LEDGF/p75, the HIV-1
Integrase binding domain and the PWWP domain, were both required for this inhibitory effect.
These data suggest that the effect of LEDGF/p75 on the transcription of the DTX3L/PARP9
genes at the chromatin level may involve not only the promoter regions but other genetic
elements as well. Alternatively, LEDGF/p75 could require the interaction with other cellular
factors that are limiting in cells that are over expressing LEDGF/p75.
LEDGF/p75 has been reported to be involved in the adaptation to cellular stress in cells
over expressing this protein; however, our data indicate that under basal endogenous conditions
LEDGF/p75 does not significantly affect the regulation of genes involved in stress response. To
clarify this potential protective effect we studied the capability of LEDGF/p75-deficient cells to
adapt to environmental stresses. Our data indicate a protective effect of LEDGF/p75 to these
stresses being necessary for cell viability under these conditions. To further understand this
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effect of LEDGF/p75 on cellular response to stress we determined the differential distribution of
LEDGF/p75-interactor proteins involved in transcriptional regulation in response to cellular
insults. We demonstrate that LEDGF/p75 influences the subcellular distribution of SSRP1 and
CDK9 in response to environmental stresses. LEDGF/p75 was required to mediate recruitment
of both SSRP1 and CDK9 to transcriptionally active complexes following these cellular insults.
In summary, our data indicate that LEDGF/p75 interacts with components of the basal
transcription machinery and of the transcriptional elongation complex, suggesting that this
protein regulates the transcription of LEDGF/p75-responsive genes at the initiation and
elongation steps of transcription. Additionally, LEDGF/p75 participates in the recruitment of the
transcriptional elongation factors SSRP1 and CDK9 to chromatin under basal conditions and in
response to cellular stresses.
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Chapter 1: Introduction
Gene Expression
The first step of gene expression, wherein RNA copies of the DNA are synthesized, is
Transcription. The RNA products are subsequently utilized for the production of proteins in the
follow on process of Translation. Transcription is broadly defined in three phases: initiation,
elongation (including: promoter clearance, proximal pausing and productive elongation) and
termination (Fig. 1) [1].

Figure 1. The phases of transcription.
This diagram illustrates the three primary phases of transcription: Initiation, Elongation and Termination. It also clarifies the
transition from initiation into productive elongation via promoter clearance and proximal pausing. Factors chosen for this
diagram are used to illustrate elongation and are not comprehensive.

Prior to initiation factors are bound to recruit the pre-initiation complex including the
RNA polymerase II (PolII). PolII requires ATP hydrolysis for remodeling of the pre-initiation
complex by TFIIH. During remodeling of the pre-initiation complex approximately11-15 DNA
base pairs at the transcription start site are unwound, allowing single-stranded DNA to enter the
active site of PolII and initiate transcription [2, 3]. After initiation the transcriptional complex
1

disassociates with promoter-sequence elements and some promoter bound factors in promoter
clearance [4]. During this step, the association between the transcription complex and the nascent
RNA are strengthened and the process is considered complete when it is associated stably [1].
The next step shown in Figure 1 boundaries the transition between initiation and productive
elongation is proximal pausing. Proximal pausing is a regulatory step that allows for maturation
of the transcriptional elongation complex and rate-limiting control of transcriptional output [5].
This process is thought to be regulated by the presence of negative elongation factor (NELF) and
DRB sensitivity-inducing factor (DSIF) [6, 7]. The DSIF complex is made up of the subunits
Spt4 and Spt5 [8, 9] and NELF contains four subunits NELF A, B, C/D and E [10].
Release from pausing is initiated by the addition of positive transcription-elongation
factor B (P-TEFb) to the transcriptional complex [9]. This complex is made up of two subunits
CDK9 and Cyclin T and has kinase activity phosphorylating Rbp1 at the Serine 2 position. Rbp1
is a subunit of PolII containing a heptapeptide repeat that is a defining characteristic
differentiating this polymerase from RNA polymerases I and III. Additionally, P-TEFb
phosphorylates NELF and DSIF [11, 12]. At this point NELF disassociates from the complex
and productive elongation can begin [7]. Of note DSIF, while repressing elongation in the
presence of NELF, once phosphorylated and absent of NELF is thought to promote elongation
[6, 8, 13]. Factors shown to aid in relief from transcriptional pausing are transcription factors IIF
and IIS (TFIIF and TFIIS), Elongin and Eleven-nineteen lysine rich in leukemia (ELL) [14, 15].
Elongation specific factors, ELL and Elongin, can be found when coimmunoprecipitated with
phosphorylated PolII and are recruited to heat shock loci [16, 17].
An important pathway involved with the transcriptional complex is the transcriptional
coupled repair (TC-NER) pathway [18]. The mechanism involved in this pathway is poorly
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understood in eukaryotes yet it is important for correcting DNA lesions and cross-linking found
during transcription and associates transiently with the transcriptional complex. Several factors
that have been identified in this pathway are: Cockayne syndrome B protein (CSB) a putative
transcription repair coupling factor [19], a structure specific DNA endonuclease XPG [20], the
PolII subunits Rbp4 and 9 [21, 22], the THO/TREX complex that functions to keep mRNA from
binding to DNA to template inappropriately [23, 24], PAF and Ccr4-Not required for efficient
TC-NER activity [18].
In eukaryotes, PolII transcription is terminated when the transcript is cleaved. This
cleavage of the new transcript is followed by polyadenylation. Polyadenylation is the addition of
multiple adenines to the 3’ end of the transcript. The cleaved 3’ product is degraded as well as
any un-polyadenylated transcripts [1]. This releases the transcript and the transcriptional
complex and its constituent factors are then disassociated from each other and from the DNA. It
has been demonstrated that RNA processing mechanisms such as: splicing, capping, cleavage,
polyadenylation, are linked to the transcription-elongation complex [25].
The process of transcription is being actively studied to identify new factors that have
roles in regulation, pausing, and repair. The Lens epithelium Derived Growth Factor
(LEDGF/p75) has been described as co-transcriptional activator linking sequence specific
transcription factors to the basal transcription machinery [26]. All the sites of interaction
described for LEDGF/p75 transcriptional regulatory activities have been derived from promoter
interactions yet the mechanism of these interactions are still poorly understood.
LEDGF/p75 Cellular Role
LEDGF/p75 is a member of the hepatoma derived growth factor family. The Hepatoma
Derived Growth Factor (HDGF) family of genes is named after its founder member. There are
3

currently 6 members in this family of genes including: HDGF, LEDGF/p75 and its splice variant
p52, and Hepatoma Derived Growth Factor Related Proteins (HRP) 1, 2, 3 and 4. Defining
characteristics for membership in this gene family are an N-terminal PWWP domain (pro – trp –
trp – pro motif) which is responsible for DNA binding [27-29] and nuclear sub-cellular
localization.
HDGF
HDGF has been shown to induce growth factor activity when over-expressed
endogenously or added exogenously [30-32]. Involvement in early tissue development has been
demonstrated for several organs including: intestine, kidney, liver and the cardio vascular system
[30, 33-36]. Following injury HDGF is involved in tissue repair of lung, vascular and colon
tissues by promoting proliferation [37, 38]. Another role of HDGF has been described in cell
survival as cell lines depleted for HDGF were more prone to induction of apoptosis [39, 40].
This protein is well studied for its involvement in carcinogenesis demonstrating an increased
expression profile in multiple tumor types [41, 42] and its involvement in metastasis makes
HDGF over-expression a marker for poor prognosis [28, 43-48]. Recently, a study of HDGF
over-expression effects on gene regulation was completed in mouse primary aortic vascular
smooth muscle cells. They found that it functioned largely as a transcriptional repressor in 66
genes and activated a small group of 9 genes. Their dataset was validated by qPCR for two
groups of genes that are involved in cardiovascular development and transcriptional regulation
[49] tying this dataset to known protein function. On casual inspection there seems to be no
overlap between this dataset and microarray data available for Human LEDGF/p75 depletion.
HRP-1, 3 and 4

4

Beyond their localization and growth factor activity very little functional data exists for
these proteins. HRP-1 and 4 are only expressed in the testis and 3 are limited to the nervous
system [50-52]. No gene regulation studies have been conducted for these proteins.
HRP-2
Expressed in many cell types this protein is the only other protein in the known Human
proteome to contain an IBD [50]. In Vitro both HRP-2 and LEDGF/p75 have the ability to bind
HIV-1 Integrase and potentiate integration [53]. An analysis of function In Vivo, however,
demonstrates that something prevents this protein from binding to chromatin sufficiently to
support HIV-1 infection despite its structural similarities to LEDGF/p75 and ability to
translocate to the nucleus [54]. One theory supported by the discrepancy is that HRP-2 contains a
much higher percentage of Serines, often in repeats. This would lend the protein to be much
more heavily phosphorylated than LEDGF/p75. Perhaps a kinase important to the endogenous
post-translational conditioning of HRP-2 is missing in E.coli. Whether the inability of HRP-2 to
bind to chromatin is due to targeting, binding of additional factors masking the PWWP, folding
conformation or Phosphorylation of binding domains is unknown. No studies have been
completed to date on HRP-2’s effect on gene regulation but due to its poor chromatin association
homologous function to LEDGF/p75 may be difficult to recreate.
LEDGF
Two splice variants, LEDGF/p75 and p52, are generated from the PSIP1 gene [55].
LEDGF proteins are ubiquitously expressed although their relative abundance varies in a tissue
specific manner. These proteins are tightly bound to chromatin during all the phases of the
cellular growth cycle. Chromatin binding is essential for a role of these proteins as general
transcriptional co-activators [56]. LEDGF proteins contain an identical N-terminal region (325
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amino acids) but differ in their C-terminus. LEDGF/p75 has a C-terminal domain implicated in
its interaction with cellular and viral proteins called the Integrase Binding Domain (IBD). The Cterminal region of LEDGF/p52, instead, is only 8 aa long and does not have a defined function
[54, 57].
LEDGF/p75 was originally isolated from a lens epithelium cDNA library and it was
reported to be a growth factor for this type of cells [29]. However, study of a LEDGF/p75-null
mouse indicated that this protein was not essential for cell survival or lens development [58-60].
Instead, these mice have musculoskeletal deformities characteristic of a disruption of the
anterior-posterior patterning. This phenotype implicated LEDGF/p75 in the regulation of
Homeobox (HOX) genes [61].
The molecular mechanism of LEDGF/p75 in the regulation of HOX genes has been
further characterized [62]. Chromatin-bound LEDGF/p75 tethers to HOX genes to the
Menin/MLL complex by interaction with the IBD. In turn, Menin/MLL modifies the expression
of the targeted genes. The genes reported to be transcriptionally influenced by the LEDGF/p75
and the Menin/MLL complex are Homeobox (HOX) A6, HOX A7, HOX A9, Meis1, CDKN2C
and CDKN1B [62]. Interestingly, a similar tethering mechanism is central to the role of
LEDGF/p75 in HIV-1 infection [58].
LEDGF/p75 has been also suggested to have a role in promoting resistance to thermal
and oxidative stressors by modulating the expression of specific genes [63-70]. The suggested
mechanism of interaction was a direct binding to heat shock element (HSE) and stress response
element (STRE) sequences in the promoter of genes implicated in cellular response to
environmental stresses. Recently LEDGF/p75 has been shown to directly influence the
transcriptional regulation of Vascular Endothelial Growth Factor C (VEGF-C) [71]. In this study
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evidences were provided demonstrating that regulation of oxidative and thermal induced stress
regulation of VEGF-C were mediated by LEDGF/p75 in an STRE dependent manner. Specific
binding to these DNA sequences, however, has been challenged, indicating that the interaction of
LEDGF/p75 with these DNA sequences may be promoter and/or tissue specifics. In addition,
these studies implicating LEDGF/p75 in transcriptional regulation of genes involved in cellular
response to stress have been conducted in cell lines expressing wild type levels of endogenous
LEDGF/p75. Constitutive expression of endogenous protein prevents evaluation of whether the
proposed role of LEDGF/p75 is essential for cell survival.
A role of LEDGF/p75 in cancer development has been also proposed. LEDGF/p75 has
been shown to have increased expression in blasts from chemotherapy-resistant human acute
myelogenic leukemia patients [64]. It also protects leukemia cells from apoptosis in vitro.
LEDGF/p75 has been demonstrated to be over-expressed in prostate cancers [72] and finally is
suggested to mediate a caspase-independent lysosomal degradation pathway [73]. Although the
molecular mechanism of LEDGF/p75 in cancer development is unknown yet; its interaction with
Cdc7:ASK, an essential DNA replication initiator throughout S-phase of the cell cycle, is
intriguing. This interaction is mediated by the IBD and was reported to stimulate the
phosphorylation activity of Cdc7:ASK on MCM2 by greater than 10-fold [74].
LEDGF/p75 involvement in HIV-1 integration
In addition to cellular proteins, LEDGF/p75 has been shown to tether the HIV-1 protein
to chromatin [56, 75, 76]. This observation suggests that HIV-1 highjack the molecular
mechanism implicated in the cellular role of LEDGF/p75 [77-79]. Direct evidence of
LEDGF/p75 critical role in HIV-1 infection has been demonstrated by the marked resistance of
LEDGF/p75-defient or -null cells to infection. Viral DNA integration is highly affected in these
7

cells. Re-expression of LEDGF/p75 wild type rescues infectivity and viral DNA integration in
the deficient cells. However, mutants lacking the ability to interact with Integrase or chromatin
fail to rescue infectivity rates.

These evidences led to the proposition of a tethering model

whereby the cellular factor LEDGF/p75 anchors the HIV-1 pre-integration (PIC) complex to the
chromatin through the binding to Integrase (Fig. 2) [77-79].

Figure 2 LEDGF/p75 functional protein domains.
The N-terminus contains domains for PWWP, nuclear localization signal (NLS), and AT Hooks that comprise the chromatin
binding region. The C-terminus contains the IBD which has been shown to bind cellular and viral proteins.

LEDGF/p75 also influences the HIV-1 DNA integration site distribution into the host
chromatin [78, 80-82]. HIV-1 preferentially targets active transcriptional units and avoids
promoter regions or CpG islands. However, in LEDGF/p75-deficient cells HIV-1 integration site
distribution is altered. The frequency of integration in genes decreases while the tendency for
targeting CpG islands increases.
Because of its role in HIV-1 DNA integration, LEDGF/p75 is an important target for
HIV-1 drug development. Cellular proteins make attractive drug targets due to a much lower
incidence of mutation than the HIV viral mutation rate of 3 x 10-5 per nucleotide base, per cycle
of replication [83, 84]. Therefore, understanding the cellular role LEDGF/p75 is critical for the
evaluation of potential toxicities of these anti-viral drugs for the host.
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PARP9 and DTX3L
This work focuses on the identification and study of several genes we will demonstrate
through multiple methods to be transcriptionally regulated by LEDGF/p75. Of these, two genes
were selected for further characterization to be used as a model system to study LEDGF/p75
transcriptional activity. The LEDGF/p75 responsive genes, as in DTX3L and PARP9, provide an
excellent model to study the transcriptional regulatory mechanism of LEDGF/p75. PARP9,
designated B aggressive lymphoma 1 (BBAP), shares a bidirectional promoter with DTX3L
named B-aggressive lymphoma and BAL1 binding partner [85] (BBAP). These proteins have
been shown to be over-expressed in chemo-resistant diffuse large B-cell lymphomas (DLBCL)
[86, 87] which are the most common adult lymphoid malignancies. Even with current medical
interventions DLBCL patients have a 50% mortality rate [88].
Structurally, PARP9 consists of a C-terminal catalytic region similar to Tankyrase and
polyADP ribose polymerase (PARP) and an N-terminal region similar to the macro domain in
histone macro-H2A. A role based on the macro domain function when drawn in proximity to a
promoter has suggested this protein represses transcriptional activity [86, 89-91]. Of note the
PARP domain in PARP9 is missing key conserved residues and has subsequently been shown to
be inactive for PARP activity [86]. DTX3L is a member of the DELTEX family and has E3
ubiquitin ligase activity [92]. Functionally this protein has also been shown to act as a shuttle to
modulate PARP9 sub-cellular localization [85]. The genes for both DTX3L and PARP9 are
located in close proximity on chromosome 3 and have been shown to be modulated by a shared,
IFNγ responsive, bi-directional promoter [85]. Additionally, there are putative binding sites for
the HSE and the STRE [85]. These DNA sequences are recognized by LEDGF/p75 in other
promoters such as the VEGF-C.

9

Dissertation goal
The goal of this research dissertation is to better understand the cellular role of
LEDGF/p75. We hypothesize that LEDGF/p75, through its interaction with the basal
transcription machinery as well as its function as a tethering molecule, is a transcriptional
regulator. By identifying genes regulated by LEDGF/p75 we will generate a model to study its
transcriptional regulation mechanism. In addition, understanding the cellular role of LEDGF/p75
could help identify potential side-effects of pharmacological inhibitors targeting this protein.
This will be considerably important considering that LEDGF/p75 is a target for anti-HIV drug
development.

10

Chapter 2: Materials and Methods
Cell Lines
The LEDGF/p75-deficient HEK 293T-derived cell line si1340/1428 [59], will be used for
transient expression of LEDGF/p75 proteins and quantitative RTPCR analysis of LEDGF/p75responsive genes transcript levels. The LEDGF/p75-deficient human CD4+ T cell line, TL3
[77], was used for gene expression profiling and stable expression of LEDGF/p75. These cells
were generated by transduction of SupT1 cells with an HIV-derived vector expressing a shRNA
against LEDGF/p75 [77]. To generate TL3 cells expressing different LEDGF/p75 and
LEDGF/p52 (WT or mutants), cells were transduced with Murine Leukemia Virus-derived
vectors expressing the different LEDGF proteins C-terminally FLAG tagged and selected in
G418 (600 µg /ml), as described previously [77]. Robust polyclonal G418-resistant cell lines
were obtained and characterized by immunoblotting with an anti-LEDGF (BD Transduction
Laboratories, catalog number 611714) or anti-FLAG monoclonal antibodies (mAbs) (Clone M2,
Sigma).
TL3-derived cell lines were grown in RPMI 1640 containing G418 (600 µg/ml) and
si1340/1428 cells will be grown in DMEM supplemented with puromycin (3 µg/ml) and
hygromycin (200 µg/ml). Both RPMI1640- and DMEM-based culture media were supplemented
with

10%

of

heat-inactivated

fetal

calf

penicillin/streptomycin.
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serum,

2

mM

L-glutamine

and

1%

Table 1. Cell Lines
The cell lines used in this work are displayed in this table. The GEO identifier can be used to download publicly available microarray data for
knockdown of LEDGF/p75 in these cell lines.
Control

Knockdown

Re-expression

GEO
-

Citation

SupT1 (TC3)

SupT1 (TL3)

SupT1 (WT)

Unpublished

293T (siScram)

293T (si1340/1428)

293T (si1340/1428LEDGF/p75WT)

GSE3485

Ciuffi et all, 2005

Jurkat (ScramJK)

Jurkat (si1340JK)

-

GSE7508

Wang et all, 2007

Gene expression profiling
RNA samples were purified from TL3 and TC3 with the Qiagen RNAEasy Miniprep kit
and sent to Roche/NimbleGen™ for quality analysis via bioanalyzer, hybridization and
microarray processing. The NimbleGen™ silicon chip technology uses 60 mer oligos targeting
the transcripts for ~24,000 RefSeq genes. The probes are designed with some 3’ bias along the
sense strand and utilize 3 probes per transcript. Normalization was completed using RMA
quantile normalization. Gene expression fold change calculations were performed with the
ArrayStar™ and GeneSpring™ software. Gene expression for HEK293T (GSE3485) and Jurkat
(GSE7508) cells were downloaded from GEO™. These gene profiles were obtained using
Affymetrix™ silicon chip technology that use 25 mer oligos targeting ~47,400 transcripts and
>38,500 genes. The probes are designed with some 3’ bias along the sense strand and utilize 11
probes per transcript.
Real-time quantitative reverse transcription-PCR
Total mRNA was purified from TC3, TL3 or WT with the Qiagen® RNAEasy Miniprep
kit. cDNA was generated with random oligonucleotides from the mRNA using the High
Capacity RNA-to-cDNA Kit from Applied Biosystems®. cDNA samples were analyzed using
qPCR and the iQTM SYBR® Green Supermix chemistry from BIO-RAD®. The data shown
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represent triplicate qPCR measurements normalized to the cDNA levels of the housekeeping
gene GAPDH and quantified using the standard curve method generated from genomic DNA.
Oligonucleotides used in the qPCRs are available upon request.

Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed using the Roche NimbleGen, Inc® ChIP protocol.
Briefly, 15 x 106 WT cells were cross-linked with 1% formaldehyde for 10 mins. on ice and
subjected to 13 rounds of sonication at 20% amplitude in a Sonics, Vibra Cell 750 watt
sonication apparatus to shear the chromatin. Low molecular weight (200-1000 bp) chromatin
fragments were obtained as verified by DNA agarose gel electrophoresis analysis. Chromatin
immunoprecipitations were performed with the following Chip-grade antibodies: anti-Flag
(Sigma, F1804), anti-TBP (Santa Cruz, sc-204) anti-CDK9 (Santa Cruz, sc-8338) or no antibody.
Antibodies (5 µg) were loaded onto magnetic beads coated with goat antibodies against mouse or
rabbit immunoglobulin (Dynabeads, Invitrogen). 5.34 x 106 cells of sheared chromatin was
incubated with antibodies coupled magnetic beads overnight at 4ºC on continuous rotation.
Immunobeads were extensively washed with and subject to decrosslinking by incubating at 65ºC
overnight. DNA was purified from decrosslinked samples using Qiaquick PCR Cleanup Kit
(Qiagen) and the presence of promoters, intragenic and untranscribed regions was analyzed using
specific primers by qPCR and the iQTM SYBR® Green Supermix chemistry from BIO-RAD®.
The data shown represent triplicate qPCR measurements of the immunoprecipitated DNA.
Oligonucleotides used in the qPCR analysis were located at promoter (only promoters well
defined in the literature were considered) and at exons located over 2.5 to 90 kB distant from the
promoter/transcription start sites. Levels of DNA corresponding to an untranscribed region of
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Chromosome 3 over 5 kB downstream of the PARP9 gene, was used for normalization.
Oligonucleotide positions and sequences are available upon request.
Cellular stress
TL3 and TC3 cells were plated at 0.02 X106 cells in 50 µl of culture medium. H2O2 and
NaCl solutions were freshly prepared and added to the culture. After 30 mins, 150ul of fresh
culture media was added. Cells were cultured for four days, harvested by centrifugation at 1000
x g for 6 mins at 4°C and the pellets were resuspended in 50 µl of PBS. Equal volume of
CellTiter-Glo® reagent (Promega) was added, mixed and luminescence was measure in a
Luminoskan Ascent microplate reader.
Immunoprecipitation
The interaction of the LEDGF/p75 with CDK9 or the FACT complex was evaluated by
immunoprecipitation using the LEDGF/p75-deficient TL3 cells engineered to express FLAGtagged LEDGF/p75 wild type (WT cells). Briefly, 18x106 WT cells were washed in PBS and
lysed for 15 mins on ice in 100µl of CSK I buffer (10mM Pipes pH6.8, 100mM NaCl, 1mM
EDTA, 300mM sucrose, 1mM MgCl2, 1mM DTT, 0.5% Triton X-100) containing protease
inhibitors (final concentration: leupeptine 2µg/ml, aprotinin 5µg/µl, PMSF 1mM, pepstatin A
1µg/ml). Cells lysed in CSK I buffer were centrifuged at 1000g for 6 mins at 4°C and the pellet
was resuspended in 100µl of CSK II buffer supplemented with protease inhibitors, 4 units of
turbo DNase (Ambion) and 11µl of 10X turbo DNase reaction buffer. DNase treatment of this
pellet was conducted at 37°C for 30 mins and then followed by extraction with (NH4)2SO4
250mM for 15 mins at 37°C. The DNase/(NH4)2SO4 treated sample was centrifuged at 22,000g
for 3 mins and the supernatant used for immunoprecipitation using goat anti-mouse Igs-coated
magnetic beads (Pierce). Beads (100µl) were previously loaded for 20 mins on ice with 3µg of
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anti-FLAG mAb diluted in CSKI buffer. Then, beads were separated from the unbound
antibodies, mixed with the DNase/(NH4)2SO4-extracted cell lysate and rotated for 2hrs at 4°C.
After this incubation, beads were washed three times in CSKI buffer and bound proteins eluted
by boiling in 30µl of Laemli sample buffer. Immunoprecipitated proteins were analyzed by
immunoblotting for the presence of CDK9 (Santa Cruz, sc-8338) and the components of the
FACT complex: SSRP1 (Santa Cruz, sc-56782) and Spt16 (Santa Cruz, sc-28734). LEDGF/p75
was detected with anti-FLAG mAb (Sigma, F1804).
Quantitative co-localization assay
Co-localization was evaluated with a confocal microscope using the Zeiss Zen software.
In order to set up this method we evaluated co-localization of LEDGF/p75 with HIV-1 Integrase.
These proteins interact during all the phases of the cell cycle. As a negative control a
LEDGF/p75 mutant lacking the Integrase Binding Domain (IBD) was used. LEDGF/p75deficient HEK 293T cells stably expressing eGFP-tagged HIV-1 Integrase (2LKD-IN-eGFP
cells) were plated at 2x105 cells in LabTek II chambered cover glass and transfected the next day
with 2ug of pFLAG-LEDGF/p75 WT or IBD deletion mutant. Eighteen hrs after transfection
fresh culture medium was added and forty-eight hours later cells were washed three times in 1 x
PBS and fixed with 4% formaldehyde-PBS for 10 min at 37°C. Then, cells were washed twice in
1 x PBS and immunostained for 2 h at 37ºC. LEDGF/p75 was detected with an anti-mouse
LEDGF mAb diluted 1/100 (clone 26, BD Transduction Laboratories) or an anti-rabbit LEDGF
polyclonal antibody (pAb) diluted 1/100 (Bethyl Laboratories, A300-848A) followed by
incubation with anti-mouse Ig coupled to Alexa Fluor 594 (10 µg / ml, Invitrogen A21203) or
with an anti-rabbit Ig coupled to Alexa Flour 488 (10 µg / ml, Invitrogen A21206).
Immunostained cells were washed and stained with DAPI. Colocalization of LEDGF/p75 with
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HIV-1 eGFP-Integrase was analyzed with a confocal microscope and the Zeiss Zen software. In
order to measure co-localization of LEDGF/p75 with proteins of the transcriptional apparatus
2x105 HeLa cells were plated in LabTek II chambered cover glasses and immunostained as
described above. Antibodies against CDK9 (Santa Cruz, sc-8338), TBP (Santa Cruz, sc-204),
RNA polymerase II (Santa Cruz, sc-900), SSRP1 (Santa Cruz, sc-56782) and Spt16 (Santa Cruz,
sc-28734) were used. Secondary antibodies, DAPI staining and colocalization analysis was
performed as described above.
LEDGF expression plasmids
The expression plasmids pFLAG LEDGF/p75, pFLAG LEDGF/p52 will be used for
transient expression experiments. These plasmids have the promoter of the human
cytomegalovirus immediate early gene, CMV promoter, driving the transcription of the LEDGF
cDNAs. In addition, the expression plasmid pEFIRES LEDGF/p75 will be also used for transient
expression experiments. This plasmid has the strong human polypeptide chain elongation factor
1α promoter driving the expression of the LEDGF/p75 cDNA (Hobbs,S. Development of a
Bicistronic Vector, 1998). The LEDGF/p75 cDNA expressed by these constructs contains seven
synonymous

mutations

in

the

target

site

of

the

twenty-one

shRNA

1340

(AAAGACAGCATGAGGAAGCGA) [59]. This shRNA is constitutively expressed in all the
LEDGF/p75-deficient cell lines used in the studies performed here [59, 77]. The LEDGF/p75
and LEDGF/p52 open reading frames were PCR amplified and cloned BamHI / ApaI into the
pCMV-FLAG expression plasmid. pCMV-FLAG was derived from pCMV-Myc [77] by
substituting Myc with the FLAG tag epitope. Myc was removed by ApaI / BglII digestion and a
DNA linker containing the FLAG sequence flanked by ApaI / BglII sticky ends was inserted.
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Stable expression of LEDGF/p75 or mutants in LEDGF/p75-deficient TL3 cells was
achieved by retroviral transduction. These proteins were expressed from the murine leukemia
virus expression plasmid pJZ308 [77]. FLAG-tagged LEDGF/p75 cDNAs were amplified by
PCR and cloned into BamHI / Sal I sites in pJZ308 to generate pJZ-LEDGF/p75-FLAG.
LEDGF/p75 mutants: IBD-, and P-A- were generated in the LEDGF expression plasmids
described above by the Phusion™ Site-Directed Mutagenesis Kit (Finnzymes, Inc). All the
constructs described in this study were verified by overlapping DNA sequencing of the complete
LEDGF cDNA [93].

Promoter activity
The evaluation of the effect of
LEDGF/p75 on the PARP9/DTX3L promoter
activity was performed with the pGL3PARP9
and pGL3DTX3L full length and minimal
promoter plasmids, which contain the human
PARP9/DTX3L

bi-directional

promoter

Figure 3. DTX3L/PARP9-luciferase construct diagrams
This diagram illustrates the sequence positions and orientation of
the full length and minimal promoters used to drive the
luciferase expression in the pGL3 plasmid.

driving the expression of firefly luciferase.
Directionality is specific to the gene referenced in the plasmid name and represented in figure 3.
The pGL3-Basic plasmid lacks any eukaryotic promoter or enhancer elements. The
DTX3L/PARP9 promoter was PCR amplified from genomic DNA derived from TC3 and
NheI/BglII inserted in frame with the sequence for luciferase expression. The resulting plasmid
drives luciferase expression via the DTX3L/PARP9 promoter. In these experiments β-
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galactosidase expression from the plasmid pCMV-β-gal was used to normalize for transfection
efficiency. This plasmid expresses β-galactosidase from the CMV promoter.

Bioinformatics analysis
All sequence information was obtained from NCBI, Entrez Gene and primer
oligonucleotide development performed in the NCBI, Primer-Blast tool. Gene annotation, gene
and probe Identifier cross-referencing and gene functional mapping analysis completed using the
Database for Annotation, Visualization and Integrated Discovery (DAVID ) v6.7.
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Chapter 3: Identification of LEDGF/p75-responsive genes
Gene expression of SupT1 by microarray
In order to identify the transcriptional profile of LEDGF/p75-deficient cells we
performed a gene expression analysis using human CD4+ T cells, SupT1 cell line, severely
deficient in LEDGF/p75 (TL3 cells) as demonstrated by immunoblot and qPCR (Fig. 4).
LEDGF/p75 transcript levels in TL3 and control TC3 cells were determined by real time PCR. In
correlation with previous data, we observed a 97.73% reduction in the endogenous levels of
LEDGF/p75 in TL3 cells as compared to TC3 control cells (Fig. 4a). These levels of knockdown
were comparable to the gene microarray data that indicated a 15.75 fold decrease (93.65%
reduction) in the LEDGF/p75 levels of TL3 as compared to TC3 cells. The gene expression
profile of TL3 cells was then compared to that of the LEDGF/p75-deficient HEK293T or Jurkat
cell lines, microarray analysis indicated that LEDGF/p75 was downregulated in these cells 11.3
and 3.88 folds, respectively (Fig. 5b).

A

B

Figure 4. Endogenous LEDGF/p75 levels.
A) Levels of LEDGF/p75 transcript were detected via Reverse
Transcriptase qPCR of total mRNA for several SupT1 cell lines used
in this work. B) LEDGF/p75 protein levels in TC3 and TL3 cells. Antialpha-tubulin was used as a loading control.
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B

A

Figure 5. Microarray sample preparation and validation of knockdown.
A) Samples met or exceeded spectrophotometer measurements and demonstrated no ribosomal RNA shearing. B) Microarray
gene expression indicates down-regulation of LEDGF/p75 in TL3 cells in accordance with published results. Numbers shown
indicate fold change of the LEDGF/p75 deficient cells lines from the control cells. For comparison HEK293T and Jurkat cell
lines were added from the GEO data.

LEDGF/p75-Responsive Genes
A total of 122 genes were identified as significantly deregulated in T L3 cells. While this
number is lower than the calculated false positive rate of 24,000 probes we consider that
analytical rigor is provided through further restricting the result set by comparison with multiple
cell lines. Taking the intersection of TL3 and si1340/1428 cells we found 8 targets. Table 1
includes the genes whose expression was modified in these LEDGF/p75-deficient cell lines and
compares them to the expression levels found in LEDGF/p75-deficient Jurkat cells. This
comparison indicated that the LEDGF/p75-responsiveness of the identified genes was not cell
type dependent and more likely the observed differences between Supt1 or HEK293T and Jurkat
cells reflected the LEDGF/p75 residual levels in these cells. In addition, bias in gene expression
determined by the method used to achieve LEDGF/p75 deficiency was excluded since different
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Table 2. Expression Levels
Expression levels of different cellular genes in LEDGF/p75-deficient human cell lines analyzed by gene microarray.
Gene Information

Probe ID

Cell Line

Fold Change

P Value

ABCA1
atp-binding cassette sub-family a (abc1) member 1

NM_005502

SupT1

-3.712

0.037

Chromosome: 17

215876_at

HEK293T
JURKAT

-2.1913
-1.6854

0.0128
0.374

NM_138287
225415_at

SupT1
HEK293T
JURKAT

-2.246
-7.649
1.1821

0.0434
0.0003
0.114

NM_014210
204774_at

SupT1
HEK293T
JURKAT

-2.085
-2.9007
1.1559

0.0073
0.0235
0.4233

NM_002056
202722_s_at
226886_at

SupT1
HEK293T
HEK293T
JURKAT

-2.353
-2.0787
-2.1482
-1.4608

0.0319
0.0002
0.0004
0.0002

NM_004004
223278_at

SupT1
HEK293T
JURKAT

-3.767
-3.1257
1.6699

0.0057
0.0476
0.46

poly (adp-ribose) polymerase family member 9

NM_031458

SupT1

-2.065

0.0371

Chromosome: 3

223220_s_at

HEK293T

-3.4574

0.065

JURKAT

1.099

0.4267

DTX3L
deltex 3-like (drosophila)
Chromosome: 3
EVI2A
ecotropic viral integration site 2a
Chromosome: 17
GFPT1
glutamine-fructose-6-phosphate transaminase 1
Chromosome: 2
GJB2
gap junction protein beta 2 26kda (connexin 26)
Chromosome: 13
PARP9

PDE9A
phosphodiesterase 9a

NM_001001567

SupT1

3.027

0.0128

Chromosome: 21

NM_001001576

SupT1

3.152

0.0199

237283_at

HEK293T

2.1311

0.0772

JURKAT

1.3498

0.6159

RORB
rar-related orphan receptor b

NM_006914

SupT1

-2.87

0.0149

Chromosome: 9

1557326_at

HEK293T

-3.5672

0.0153

JURKAT

-2.7082

0.4218

NM_014604

SupT1

-2.033

0.0185

1557052_at

HEK293T

-5.3125

0.0001

JURKAT

2.2375

0.1114

TAX1BP3
tax1 (human t-cell leukemia virus type I) binding
protein 3
Chromosome: 17
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methods, lentiviral transduction (SupT1-derived cells) and plasmid transfection (HEK293T- and
Jurkat-derived cell lines), were used to deliver the shRNA targeting LEDGF/p75 in these cells.
Similarly, gene expression profiles of LEDGF/p75-deficient Supt1, HEK293T or Jurkat cells
were performed in different laboratories and using different microarray systems, excluding any
potential bias in the results due to the method of gene expression analysis employed. Therefore,
genes found to be deregulated in LEDGF/p75-deficient Supt1 and HEK293T cells are likely to
be bona fide LEDGF/p75-responsive genes and were considered for further analysis.
LEDGF/p75 does not affect transcription of stress response genes
LEDGF/p75 was reported to regulate transcription of stress-responsive genes by binding
to heat shock (nGAAn, where n indicates any nucleotide) and stress-related [(T/A)GGGG(A/T)]
elements in their promoters [94]. The nGAAn sequence is very short lacking specificity,
therefore we only analyzed the presence of the stress-related [(T/A)GGGG(A/T)] element in the
promoters of the LEDGF/p75-responsive genes. We limited our analysis to the promoters of
PARP9/DTX3L, ABCA1, GFPT1 and HoxA9 that have been previously well characterized. This
stress-related element was found on these promoters near the transcription start site in a copy
number ranging from 2 to 7. These results support previous observations linking the presence of
these regulatory DNA sequences with LEDGF/p75 transcriptional activity.
Importantly, LEDGF/p75-deficiency in SupT1 or HEK293T cells was not associated to
deregulation of genes implicated in response to environmental stresses. Detailed analysis of the
expression of these genes (Table 2) indicated that their expression is not deregulated in cells that
are chronically depleted of LEDGF/p75. Interestingly, LEDGF/p75 was not found to be
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Table 3. Stress Response Genes
Gene microarray analysis of the expression of several cellular stress-responsive genes in LEDGF/p75-deficient cells.

Gene Information

ID

ADH1A
alcohol dehydrogenase 1A (class I), alpha polypeptide
Chromosome: 4

ADH7
Alcohol dehydrogenase 7 (Class IV)
Chromosome: 4
ALDH1A1
aldehyde dehydrogenase 1 family, member A1
Chromosome: 9
ALDH1A2
aldehyde dehydrogenase 1 family, member A2
Chromosome: 15
CRYAB
Alpha B Crystallin
Chromosome: 11
HSPA2
heat shock 70kDa protein 2
Chromosome: 14
HSPB1
Heat shock protein 27
Chromosome: 7
MAOA
Monoamine oxidase A
Chromosome: X

PRDX6
Antioxidant protein 2 gene
Chromosome: 1

23

Cell Line

Fold Change

P Value

NM_000667
243544_at
209614_at
209613_s_at
209612_s_at
207820_at
206262_at
1559240_at

SupT1
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293
HEK293

-1.1680
-0.4150
0.2008
0.8144
-0.1637
0.0083
0.0238
0.0411

0.5630
0.3435
0.5782
0.7068
0.7089
0.8332
0.9243
0.4773

NM_000673
210505_at

SupT1
HEK293

1.1060
-1.4061

0.2240
0.2394

NM_000689
212224_at

SupT1
HEK293

-1.3300
-4.6933

0.3150
0.0705

NM_003888
207015_s_at
207016_s_at

SupT1
HEK293
HEK293

1.0450
-1.3942
-1.5549

0.7190
0.0735
0.0039

NM_001885
209283_at

SupT1
HEK293

1.1630
-1.2807

0.4320
0.9355

NM_021979
211538_s_at

SupT1
HEK293

1.1330
-1.4545

0.6500
0.0021

NM_001540
NM_024410
201841_s_at

SupT1
SupT1
HEK293

1.2720
-1.1060
-3.9951

0.3740
0.2850
0.0095

NM_000240
212741_at
204389_at
204388_s_at

SupT1
HEK293
HEK293
HEK293

1.0390
-1.1840
1.3573
-1.2745

0.8220
0.5200
0.4635
0.7563

NM_004905
238951_at
242751_at
200845_s_at
200844_s_at

SupT1
HEK293
HEK293
HEK293
HEK293

1.2360
1.1562
1.5191
-1.0237
-1.1493

0.0076
0.3109
0.0267
0.5354
0.0482

specifically associated with these genes in a genome-wide location analysis either [82].
In order to evaluate whether LEDGF/p75-deficient SupT1 cells were more sensitive or
not to environmental stresses, TL3 and TC3 cells were subjected to oxidative and osmotic stress
and cell viability was measured. Data in figure 6a indicate that LEDGF/p75 deficient cells lines
are greater than 2 fold more susceptible to oxidative damage than endogenous LEDGF/p75 and
A

B

Figure 6. LEDGF/p75 mediated cell survival.
A) Oxidative stress susceptibility. Cells were treated with varying concentrations of H2O2 and ATP was analyzed 4 days post
treatment. Standard deviation calculated from duplicate treatments. B) Osmotic stress susceptibility. Cells were treated with
varying concentrations of NaCl and ATP was analyzed 4 days post treatment. Standard deviation calculated from triplicate
treatments.
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viability declined linearly for all cell lines in a dose dependent manner. Interestingly, the reexpressed LEDGF/p75 had a greater protective effect against oxidative damage. Similarly, an
increase in cell susceptibility to osmotic stress was seen in LEDGF/p75 deficient cells (Fig. 6b).
In summary, these data demonstrated that in cells chronically depleted of LEDGF/p75 the
expression of genes implicated in cellular response to stress are not altered under non-stress
conditions. However the ability of cell to survive stress is reduced in LEDGF/p75-deficient cells.
It suggests that LEDGF/p75 regulates transcription of these genes during stress.
LEDGF/p75 does not affect transcription of Menin responsive genes
In addition, we did not find either in these two LEDGF/p75-deficient cell lines a consistent
deregulation in the expression of Hox A or other genes found to be regulated by the interaction
of LEDGF/p75 with the Menin/MLL complex (Table 3). These results suggested that in cells
chronically depleted of LEDGF/p75 other transcriptional regulators could adopt LEDGF/p75
transcriptional roles.
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Table 4. Leukemogenic Genes
Gene microarray analysis of the expression of leukemogenic genes reported to be regulated by LEDGF/p75.
Gene Information

ID

Cell Line

Fold Change

P Value

SupT1

-1.06

0.856

HEK293

-1.073

0.194

CDKN1B
cyclin-dependent kinase inhibitor 1B (p27, Kip1)

NM_004064

Chromosome: 12

209112_at

CDKN2C
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)

NM_001262

SupT1

-1.319

0.216

Chromosome: 1

NM_078626

SupT1

-1.394

0.153

211792_s_at

HEK293

-1.0007

0.912

204159_at

HEK293

-1.5362

0.0006

SupT1

1.173

0.312

208557_at

HEK293

1.8691

0.0005

239915_at

HEK293

1.8492

0.0375

HOXA6
homeobox A6

NM_024014

Chromosome: 7

HOXA7
homeobox A7

NM_006896

SupT1

-1.167

0.616

Chromosome: 7

206847_s_at

HEK293

1.1939

0.2653

206848_at

HEK293

1.7284

0.0003

SupT1

-1.223

0.05

209905_at

HEK293

2.0865

0.0019

231365_at

HEK293

1.2962

0.2344

214651_s_at

HEK293

1.9129

0.0003

NM_002398

SupT1

-1.109

0.551

242172_at

HEK293

-1.1189

0.4914

1559477_s_at

HEK293

-1

0.8136

204069_at

HEK293

-1.25

0.0019

HOXA9
homeobox A9

NM_152739

Chromosome: 7

MEIS1
Meis 1
Chromosome: 2

26

Chapter 4: Validation of LEDGF/p75 transcriptional regulation.
Validation of LEDGF/p75 responsive genes
In order to verify the significance of LEDGF/p75 for transcription of the identified
LEDGF/p75-responsive genes (Table 1), we measured their mRNA levels in SupT1 cells
expressing or not LEDGF/p75 by real-time quantitative reverse transcription PCR (qRT-PCR).
Levels of GAPDH mRNA, a housekeeping gene non-responsive to LEDGF/p75, were used for
normalization of the samples. As indicated in Figure 7 the mRNA levels of most of these genes
were specifically downregulated in LEDGF/p75-deficient cells and the level of down regulation
generally correlates with the microarray data (Table 1). Genes EVI2A and PDE9A were not
found deregulated by qRT-PCR analysis and were not considered for further analysis. The

Figure 7. qRT-PCR Validation of Transcript.
Total mRNA was harvested from control and LEDGF/p75 knockdown cells for each cell line. cDNAs were generated via
Reverse Transcriptase reactions and genes were measured by qPCR. Standard deviations were calculated from triplicate qPCR
measurements and are representative of multiple experiments.
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remaining genes included in figure 2 are LEDGF/p75-responsive genes. In further support,
PARP9 and DTX3L genes were also verified to be downregulated 3.45 and 7.64 fold,
respectively, in LEDGF/p75-deficient HEK293T cells by qRT-PCR. Interestingly, the
transcription of the LEDGF/p75-responsive genes PARP9 and DTX3L genes is directed from a
shared bidirectional promoter.
LEDGF/p75 inhibits the activity of the DTX3L/PARP9 promoter
To determine if LEDGF/p75 was directly acting on promoter sequences subsequently
influencing mRNA levels of these genes we selected for further analysis DTX3L and PARP9.
These genes share a bi-directional promoter, are significant by microarray and qPCR analysis of
transcript, and have a phenotype in chemo-resistance similar to LEDGF/p75 depletion. We
cloned these full length promoters upstream of the firefly luciferase gene for analysis (Fig 3).
Promoter functionality was evaluated by determining the responsiveness of these promoters to
stimulation with IFNγ. Data in figure 8a demonstrate that both full length promoters responded
to IFNγ, as reported.
Next we evaluated the effect of LEDGF/p75 over-expression on the activity of these
reporter systems. Activity was measured in fold change of LEDGF/p75 vs. the empty plasmid.
Data in 8b demonstrated a repressive activity of LEDGF/p75 on these promoters. This reduction
was not expected and is contradictory to our previous findings. To evaluate whether this effect
was not due to an assay specific deleterious effects we titrated the levels of the LEDGF/p75 reexpressed, the amount of IFNγ used for activation, the amount of luciferase reporter plasmids
transfected, as well as the incubation times (Supplemental – A. Promoter Experiments). In all of
these studies we obtained the same LEDGF/p75-mediated inhibitory effect. To determine if this
effect was due to promoter competition between the plasmid expressing LEDGF/p75 and the
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luciferase reporter plasmid we expressed LEDGF/p75 from two different plasmids using
different promoters. Using these plasmids we systematically observed a similar inhibition of
LEDGF/p75 regulated promoter activity (Fig 8b).

A

B

C

D

Figure 8. DTX3L/PARP9 promoter response.
A) DTX3L/PARP9 promoter is IFNγ responsive. The results are shown in relative light units corrected for the loading control
β-Galactosidase. Samples were either treated with 0 or 150U IFNγ 24 hrs after transfection. B) LEDGF/p75 inhibits
transcriptional activity of the DTX3L and PARP9 full length promoters in the presence of IFNγ activation at 24 hrs.
Results are displayed as % of control between LEDGF/p75 and an empty plasmid. All samples are corrected for β-Galactosidase
levels as a loading control. LEDGF/p75 was expressed from a CMV immediately early promoter-driven expression plasmid
p1012 or from a transcriptional elongation factor promoter-driven expression plasmid pEFIRES. Standard deviations calculated
from two biological replicates, exception PARP9 for p1012 was only completed once. C) Shared minimal promoters for
DTX3L and PARP9 are IFNγ responsive. The results are shown in relative light units corrected for the loading control βGalactosidase. Samples were either treated with 0 or 150U IFNγ 24 hrs after transfection. D) LEDGF/p75 inhibits
transcriptional activity of the DTX3L and PARP9 minimal promoter in the presence of IFNγ activation. Results are
displayed as fold change between LEDGF/p75 and the empty plasmid control. All samples are corrected for β-Galactosidase
levels as a loading control using the pEFIRES plasmid to deliver LEDGF/p75. Two different orientations of the same minimal
promoter were evaluated. Standard deviations calculated from two biological replicates.
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We next investigated if the inhibitory effect of LEDGF/p75 was specific to the IFNγ
activation of this promoter. Very similar inhibition was observed in the presence and absence of
IFNγ (Supplemental – A. Promoter Experiments). This led us to conclude that the LEDGF/p75
inhibition of the DTX3L/PARP9 shared promoter was independent of the IFNγ response.
In addition, we evaluated the effect of LEDGF/p75 on the activity of the shared
DTX3L/PARP9 minimal promoter using the system described above. We first demonstrated the
functionality of the cloned minimal promoter by evaluating responsiveness to IFNγ (8c).
Subsequently we evaluated the effect of LEDGF/p75 on the activity of this minimal promoter.
As indicated in figure 8d, LEDGF/p75 also inhibited the activity of this promoter.
All our experimental data unambiguously indicate that LEDGF/p75 expression has an
inhibitory effect on the DTX3L/PARP9 promoter activity that is independent of IFNγ activation.
However, these data are in contradiction with the observed decreased in DTX3L and PARP9
mRNA levels observed in the microarray analysis and by the direct quantization of these mRNAs
by RTPCR. Therefore our data clearly indicated that it is unlikely that the effect of LEDGF/p75
deficiency on DTX3L/PARP9 mRNA levels is due to regulation of the promoter activity.
Therefore we next plan to evaluate the role of LEDGF/p75 in regulation of transcriptional
elongation.
Effect of LEDGF/p75 deficiency on activation of DTX3L/PARP9
The activity of the shared bidirectional promoter of PARP9 and DTX3L is regulated by
IFNγ. To evaluate if LEDGF/p75 influences both basal and activated gene transcription we
stimulate LEDGF/p75-deficient and control SupT1 cells with IFNγ and the mRNA levels of
PARP9 and DTX3L was determined by qRT-PCR. Although basal levels of PARP9 and DTX3L
were decreased in LEDGF/p75-deficient cells, IFNγ-treatment eliminated these differences
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Figure 9. Effect of IFNγ on the PARP9 and DTX3L mRNA levels.
TL3 to TC3 cells were treated with IFNγ and PARP9 and DTX3L mRNA levels were determined by real-time quantitative
reverse transcription-PCR 48 hrs after stimulation. Standard deviation calculated from triplicate qPCR measurements.

indicating that LEDGF/p75 was dispensable during activated transcription of these genes (Figure
9). These data also exclude a potential permanent damage of this shared promoter caused during
the generation of the LEDGF/p75-deficient SupT1 cells.
Effect of LEDGF/p75 core domains on transcript and promoter activity
We have observed that endogenous LEDGF/p75 increases the levels of transcript for both
DTX3L and PARP9, yet in direct contradiction the re-expressed LEDGF/p75 is inhibitory by
promoter activity analysis. To investigate whether this effect was specific to the promoter
activity experiment or an issue of broader impact we analyzed the effect of various LEDGF/p75
deletion mutants for both transcript and promoter activity. Though endogenous (TC3) could not
be determined for the promoter activity system due to inherent limitations, the correlation
between the transcript and promoter activity is very high when the protein is under nonendogenous promoter control. Data in Figure 10 clearly demonstrate that the effect of inhibition
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Figure 10. Effect of LEDGF/p75 core domains on Transcript and Promoter Activity.
This figure compares as % of control either transcript TC3 vs. TL3 or for promoter activity labeled mutant vs. an empty plasmid.
For transcript analysis total mRNA was subjected to reverse transcriptase conversion to cDNA and analyzed via qPCR. Standard
deviation calculated from triplicate qPCR measurements. The promoter experiments were conducted 24 hours post transfection.
All samples are corrected for β-Galactosidase levels as a loading control. Standard deviation calculated from two biological
replicates.

by the re-expressed LEDGF/p75 is not limited to assay specific off target effects but as a result
of a non endogenous expression of the protein. This effect can be abrogated (Figure 10) by
deletion of IBD, which is the only domain demonstrated to bind other cellular and viral factors,
or deletion of the chromatin binding domain (PA-) that renders LEDGF/P75 a non-chromatin
bound protein. These data indicate that both the chromatin binding and Integrase binding
domains play key roles in the normal function of LEDGF/p75 mediated transcription. As well,
the IBD and WT results together suggest that the IBD is a site of interaction for either a repressor
which is not bound to the complex when the domain is no longer present or cofactor which is
being sequestered by over expression of LEDGF/p75 under non endogenous conditions causing a
rate limiting inhibition via paucity of the cofactor.
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Chapter 5: Role of LEDGF/p75 in Transcriptional Elongation
LEDGF/p75 occupies both promoter and intergenic regions of target genes.
A function of LEDGF/p75 as a transcriptional coactivator at the level of the promoter has
been demonstrated in different experimental models, suggesting a role in the formation of the
transcription initiation complex. However, the exclusive location of LEDGF/p75 at the promoter
region is unlikely since this cellular factor facilitates HIV DNA integration inside genes that are
actively transcribed. This suggests that at a genomic level, LEDGF/p75 should also be associated
with intragenic regions that are actively transcribed. In support of this possibility, LEDGF/p75
was found genome-wide primarily downstream the transcription start sites and associated with
epigenetic markers of active transcription.
Therefore, in order to evaluate the location of LEDGF/p75 on responsive genes we
performed chromatin immunoprecipitation (ChIP). ChIP was performed in LEDGF/p75-deficient
cells engineered to express FLAG-tagged LEDGF/p75 (WT). These cells were fixed, sonicated
and subjected to ChIP with a FLAG antibody or no antibody. ChIPed DNA was used for qPCR
determination with specific primers for promoter and exons of the LEDGF/p75-responsive
genes. To prevent ambiguous interpretations, promoter occupancy was only analyzed for those
genes where a well characterized promoter has been described. Primers used in qPCR analysis
for promoter and exon regions target sequences that were separated for more than 2.5 Kbs, a
distance more than > 2.5 times longer than the length of the fragments obtained after chromatin
shearing. In addition, DNA levels in the ChIP samples corresponding to the different promoter or
intragenic regions analyzed were normalized against the DNA levels detected with a primer
hybridizing to an untranscribed region located >5 Kbs downstream the end of the PARP9 gene.

33

Figure 11. Promoter and Exon Occupancy.
A) Location of LEDGF/p75 on the transcription unit of LEDGF/p75-responsive genes. The location of LEDGF/p75 or the
TATA binding protein on promoters or intragenic regions of LEDGF/p75-responsive genes was determined by chromatin
immunoprecipitation and quantitative real time PCR analysis. As control, the occupancy of the TBP on PARP9 was evaluated. In
addition, the effect of IFNγ on LEDGF/p75 occupancy of PARP9 transcription unit is represented. DNA levels measured for
these promoters and exons were normalized against DNA levels of a non-transcribed region downstream of PARP9 gene present
in the chIP DNA.

Data in figure 11 indicated that LEDGF/p75 was specifically associated to both
promoters and exons of LEDGF/p75-responsive genes ABCA1, GFPT1, and PARP9. However,
binding to HOXA9 promoter was highly variable between replicates although it was found inside
this gene. As a control, DNA extracted from WT cells and was subjected to chip with an antiTBP antibody. TBP is a component of the transcriptional initiation complex and therefore reside
exclusively on the promoter region. ChIPed DNA was used in qPCR analysis to quantify the
levels of PARP9 promoter and exons. Data in figure 11 clearly indicate that TBP was exclusively
associated with promoter DNA demonstrating the validity of our analysis.
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LEDGF/p75 was found also inside RORB and TAX1BP3 but not of GJB2 although the
transcription of the later gene was clearly downregulated in the microarray and qRT-PCR
analyses (Table 1 and Figure 7). It is possible that the regulation of the expression of GJB2 by
LEDGF/p75 is not direct. Instead, LEDGF/p75 could regulate other factors directly involved in
the transcriptional regulation of GJB2. Alternatively, LEDGF/p75 could regulate this gene by
interaction only at the promoter. Promoter occupancy was not evaluated for all of the genes in
Figure 11 because of a lack of characterization of these promoters. As an additional control, we
evaluated the occupancy of exons in the genes EVI2A and PDE9A (Fig. 11). The expression of
these genes was not affected by the LEDGF/p75-deficiency as evaluated by qRT-PCR analysis.
In correlation with this, LEDGF/p75 was not enriched inside PDE9A. EVI2A, however, was
highly variable between replicates possibly indicating some other downstream mechanism
involved in its transcription.
LEDGF/p75 co-immunoprecipitates with members of the elongation complex
Our data indicate that LEDGF/p75 specifically locates at the promoter and inside
LEDGF/p75-responsive genes and that this location correlates with the transcription activity of
the gene. Therefore, we evaluated the interaction of LEDGF/p75 with members of the
transcriptional elongation and initiation complexes to determine if LEDGF/p75 forms a part of
any of these complexes.
LEDGF/p75-deficient SupT1 cells (TL3 cells) and TL3 cells expressing FLAGtagged LEDGF/p75 were subjected to immunoprecipitation with an anti-FLAG mAb.
Immunoprecipitated proteins were then evaluated by immunoblotting for the presence of two
different components of the elongation complex, CDK9 and the heterodimer Spt16 (Suppressor
of Ty 16 homolog) / SSRP1 (Structure Specific Recognition Protein 1) or FACT complex.
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CDK9 in association with cyclin T1 form the
positive transcription elongation factor b (P-TEFb)
that phosphorylates the C-terminal domain of the
large subunit of the Pol II licensing this enzyme to
transition
elongation.

from
The

transcription
FACT

initiation

complex

to

remodels

nucleosomes in an ATP-independent fashion
allowing Pol II to access the DNA during
transcriptional elongation.
About fifty percent of the cellular CDK9 is
in a high molecular weight complex that is not
associated to chromatin and as a result this form is
not participating in transcriptional elongation. The

Figure 12. Interaction with members of the
transcriptional elongation complex.
Chromatin-bound proteins were isolated from TL3 and
WT cells by DNAse and salt treatment and FLAGtagged LEDGF/p75 was immunoprecipitated with an
anti-FLAG mAb. The presence of CDK9, and the
FACT complex (Spt16 and SSRP1) was evaluated in
the immunoprecipitated proteins by immunoblotting
with specific antibodies.

other portion of CDK9 is recruited to chromatin and
engaged in transcriptional elongation. The high molecular weight form can be extracted to a
soluble fraction when cells are lysed in buffers containing less than 100 mM NaCl and Triton X100. However, solubilization of the chromatin-bound active CDK9 form requires higher salt
concentration or DNase treatment. Similarly, SSRP1 exists in a chromatin-bound and a nonchromatin bound fractions. Therefore, in order to evaluate the interaction of LEDGF/p75 with
the CDK9 and FACT complex forms involved in transcriptional elongation, we lysed the cells in
a buffer containing 0.1% Triton X-100 and 100 mM NaCl (CSK1 buffer). This buffer has been
reported to extract only chromatin non-bound proteins. Chromatin-bound proteins were then
released from the insoluble fraction of the CSKI-cellular lysate by extensive treatment with
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DNase. The DNase-released chromatin-bound proteins were then subjected to FLAG
immunoprecipitation and coimmunoprecipitated proteins were evaluated for the presence of
CDK9 and the FACT complex by immunoblotting with specific antibodies. Results included in
Figure 12 indicate that LEDGF/p75 is associated in vivo with the forms of CDK9 and the FACT
complex likely to be engaged in transcriptional elongation. Since chromatin-bound proteins were
extracted by DNAse treatment before immunoprecipitation, the association of LEDGF/p75 with
these members of the transcriptional elongation complex is independent of DNA.
LEDGF/p75 co-localizes with members of the transcription complex.
To further verify the interaction of LEDGF/p75 with other proteins involved in
transcription we evaluated the co-localization of LEDGF/p75 with the initiation complex protein
TBP, and the elongation complex proteins CDK9 and SSRP1, as well as colocalization with Pol
II (Fig. 13). Colocalization was evaluated using quantitative confocal microscopy analysis. As
control, we calculated the co-localization of HIV-1 Integrase (IN) with LEDGF/p75 WT or a
mutant lacking the Integrase binding domain (IBD-). In correlation with previously reported
data, LEDGF/p75 WT fully co-localized with IN and this co-localization was lost upon deletion
of IBD (Fig. 13a). Weighted colocalization percentage was calculated for these analyses and is
represented in figure 13b. LEDGF/p75 WT significantly co-localized with TBP, CDK9, SSRP1,
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Figure 13. Quantitative colocalization of
LEDGF/p75
with
proteins
of
the
transcriptional machinery.
A)
(a-I)
Colocalization
controls.
Colocalization of LEDGF/p75 and HIV
integrase were used as controls.
LEDGF/p75-deficient HEK293T cells stably
expressing Myc-tagged HIV-1 integrase
were
transiently
transfected
with
LEDGF/p75 WT or a mutant lacking the
integrase-binding
domain
(IBD).
LEDGF/p75 and integrase were detected
with anti-LEDGF and anti-Myc antibodies,
respectively. (a-II) Colocalization of
LEDGF/p75 with TBP, CDK9, RNA
polymerase II and SSRP1. HeLa cells
were fixed and immunostained with specific
antibodies. Histograms and representative
cells are shown. B) Experiment in section
(a) was quantified. Standard deviations
indicated co-localization values found in
ten different cells randomly selected.

B
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and Pol II. Co-localization with CDK9 and the SSRP1 validated the results of the
immunoprecipitation experiment included in figure 12. Results presented in figures 5 and 6
clearly indicate that LEDGF/p75 interacts with components of the transcriptional initiation and
elongation complexes.
LEDGF/p75 influences binding of CDK9 to the intragenic regions of target genes.
In order to clarify the role LEDGF/p75 is playing in transcriptional elongation we next
investigated the LEDGF/p75 recruitment of CDK9 to the intragenic regions of ABCA1, PARP9,
RORB and TAX1BP3. These genes were selected for analysis due to the significance and
consistency of their exon response from the prior occupancy study. A ChIP was performed
comparing samples of WT and TL3. These chromatin samples were prepared as previously
described and immunoprecipitated using 5 µg of CDK9 rabbit pAb. After decrosslinking and
cleanup samples were analyzed via qPCR. As control we included an analysis of the PARP9

Figure 14. LEDGF/p75 mediated enrichment of CDK9 on the exons of target genes.
ChIPs were performed using sonicated chromatin isolated from WT and TL3 cell lines. These samples were
immunoprecipitated using 5 µg of anti-CDK9 and analyzed via triplicate qPCR measurements. Standard deviations
represent two biological replicates.
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promoter occupancy a region that should not be enriched when immunoprecipitated by an
elongation specific factor. Data in Figure 14 clearly demonstrate a LEDGF/p75 enrichment of
CDK9 on the exons of these genes. As expected CDK9 fails to enrich the promoter sequence of
PARP9 demonstrating the validity of this analysis.
As further demonstration, an analysis of the protein distribution of SSRP1 and CDK9
were performed. Cells were lysed in PBS + Triton buffer and fractionated via centrifugation.
These elongations factors are distributed to chromatin bound (P1 fraction) and a chromatin nonbound (S1 fraction) subcellular compartments. Only the protein found in P1, chromatin-bound, is
A

B

C

Figure 15. LEDGF/p75 mediated binding of CDK9 and SSRP1 to the chromatin.
A) Fractionation. Cells were harvested from TC3, TL3 and WT and subjected to a PBS+Triton lysis buffer. Samples
were fractionated via centrifugation. Proteins were detected using specific antibodies. Results are representative of
multiple experiments. B) CDK9 Densitometry. Values corrected for background and displayed as a ratio of P1 / S1.
Standard deviations calculated from two biological replicates. C) SSRP1 Densitometry. Values corrected for
background and displayed as a ratio of P1 / S1. Standard deviations calculated from two biological replicates.
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involved in transcription or DNA repair. Data in Figure 15 clearly demonstrates that the levels of
transcriptionally active (P1 fraction) CDK9 and SSRP1 is reduced in cells lacking LEDGF/p75.
These data indicate that LEDGF/p75 is acting to recruit elements of the transcriptional
elongation apparatus to the chromatin. Whether LEDGF/p75 is actively recruiting these proteins
or merely acting as a stabilizing element of the elongation complex is still unknown.
LEDGF/p75 mediated localization of SSRP1 to acidosis and oxidative stress events.
During the analysis of the elongation factor binding it became evident that the fractional
localization of these factors can be influenced by stressors. Additional fractionation experiments
were run to elucidate some of the different stress factors that influence the LEDGF/p75 mediated
A

B

anti-CDK9

anti-SSRP1

Figure 16. pH effect on LEDGF/p75 mediated chromatin bound CDK9 and SSRP1.
A) anti-CDK9 pH fractionation. Cells were harvested from TC3, TL3 and WT and subjected to a PBS+Triton lysis buffer.
Samples were fractionated via centrifugation. Proteins were detected using specific antibodies. Results are
representative of multiple experiments. CDK9 Densitometry. Values corrected for background and displayed as a ratio
of P1 / S1. B) anti-SSRP1 pH fractionation.
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distribution of SSRP1 and CDK9. To test pH conditions samples from TC3, TL3 and WT were
resuspended in sterile PBS buffers of the appropriate pH and incubated for 90 minutes in the 37C
waterbath. After incubation Triton+DTT was added to lyse the cells. Lysates were fractionated
by centrifugation and proteins detected with specific antibodies. The data from the densitometry
analyses in Figure 16 excludes background signal and indicates that CDK9 recruitment to the
chromatin is not altered with or without LEDGF/p75. SSRP1, however, has a twofold higher
chromatin bound protein as compared to soluble protein in the presence of acidic conditions.
Cystosolic pH is ~7.2 and nuclear pH is ~7.6 on average. Acidosis can be triggered by even
slight reductions in pH.

A

B

Figure 17. H2O2 effect on LEDGF/p75 mediated chromatin bound CDK9 and SSRP1.
A) anti-CDK9 H2O2 fractionation. Cells were harvested from TC3, TL3 and WT and subjected to a
PBS+Triton lysis buffer. Samples were fractionated via centrifugation. Proteins were detected using
specific antibodies. Results are representative of multiple experiments. CDK9 Densitometry. Values
corrected for background and displayed as a ratio of P1 / S1. Standard deviations calculated from two
biological replicates. B) anti-SSRP1 H2O2 fractionation.
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Next we subjected cells to similar treatments with 500 µM H2O2. In the Figure 17
densitometry we see two fold increases in LEDGF/p75 mediated chromatin bound SSRP1 and
CDK9 for both endogenous and re-expressed cell lines. No significant change was seen for either
factor in LEDGF/p75 deficient cells. This data clearly indicates that the transcriptional
elongation apparatus becomes more active in response to cellular stress and that LEDGF/p75
facilitates the binding of the transcription factors SSRP1 and CDK9 to the chromatin. These data
are in direct correlation with the observed cell stress susceptibility of LEDGF/p75 deficient cells
and elucidate a role for LEDGF/p75 in protection from cellular stress through its interaction with
transcription factors in the elongation complex.
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Chapter 6: Discussion
A role of LEDGF/p75 in transcriptional regulation at promoters regions has been
extensively described, yet the participation of LEDGF/p75 in other steps of transcriptional
regulation has not been evaluated. Co-transfection of LEDGF/p75 with several promoters of
stress responsive genes indicated that LEDGF/p75 regulates the transcription of these genes by
binding to specific DNA sequences in their promoters. However, the specific interaction of
LEDGF/p75 with these sequences was not supported in an independent study. At the molecular
level, it was demonstrated in in vitro studies that LEDGF/p75 activated transcription of reporter
promoters by linking promoter-specific transcription factors with components of the basal
transcription machinery. In addition, it was demonstrated LEDGF/p75 regulates the
transcriptional activity of the Hox A9 gene by tethering to the promoter of this gene the histone
methyl transferase Menin/MLL complex. Interestingly, a similar molecular tethering mechanism
is involved in the role of LEDGF/p75 in HIV DNA integration.
LEDGF/p75 tethers the HIV pre-integration complex to the host chromatin facilitating
viral DNA integration into the host DNA. This interaction targets HIV to integrate inside genes
that are actively transcribed. In correlation with this, genome-wide location of LEDGF/p75
indicated that this protein is enriched inside actively transcribed genes. Our data further
demonstrate that LEDGF/p75 is located inside genes forming part of the transcriptional
elongation complex. In this study we have identified a group of genes whose expression is
downregulated in human LEDGF/p75-deficient cells of different lineage. We found LEDGF/p75
present at the promoter and inside these LEDGF/p75-responsive genes and the level of
occupancy at these locations correlated with their transcriptional activity. In addition,
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LEDGF/p75 colocalizes in vivo with TBP (transcription initiation complex marker), CDK9,
FACT complex (transcriptional elongation complex markers), and Pol II. Interaction with the
transcriptional elongation active forms of CDK9 and the FACT complex was further evidenced
to occur in vivo and to be independent of DNA. Our data suggest that in LEDGF/p75-responsive
genes LEDGF/p75 interacts at the promoter level with components of the transcriptional
initiation complex and then travels with the elongation complex during active transcription.
Here we demonstrate that LEDGF/p75 is vital to cell survival when exposed to oxidative
and osmotic stressors. Our data also positively link this phenotype of cell survival with
LEDGF/p75’s participation in the transcriptional elongation complex demonstrating an increase
in the amount of SSRP1 and CDK9 recruited to the chromatin in the presence of LEDGF/p75
during stress responses to pH and oxidative insult. Further, LEDGF/p75 could be involved in
tethering the histone methyltransferase Menin/MLL complex to the transcription unit to catalyze
trimethylation of lysine 4 on histone H3, an epigenetic mark associated with transcriptionally
active chromatin and activity of P-TEFb. A similar role has been reported for the yeast
COMPASS (Complex Proteins Associated with Set1) complex which is a functional analog of
the human MLL. The COMPASS complex is recruited by Pol II (phosphorylated at serine 5 in
the C-terminal domain) to trimethylate lysine 4 on histone H3, a modification highly correlated
with transcriptional elongation. It is also possible that LEDGF/p75 participates in attracting this
subset of genes to other components of the elongation complex. Similarly to LEDGF/p75, Brd4
and other members of the BET (bromodomain and ET domain) family proteins associate to
chromatin during all phases of the cell cycle including mitosis. Therefore, it is plausible that
LEDGF/p75 could contribute to the transmission of transcriptional memory during mitosis from
different cell generations as has been proposed for the BET family proteins.
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In addition, we postulate that the presence of LEDGF/p75 at the elongation complex will
facilitate HIV DNA integration by allowing the virus to exploit the cellular function of other
members of this complex. For instance, the FACT complex could assist the HIV preintegration
complex to gain access to the host DNA in a similar manner that FACT facilitates DNA access
to the RNA polymerase during transcription [95]. Similarly, the interaction of LEDGF/p75 with
the component of the FACT complex, SSRP1, could facilitate post-integration DNA repair [9698]. SSRP1 has a role in transcription-coupled DNA repair. This is a sub pathway of the
nucleotide excision repair pathway that is responsible for removing DNA lesions in actively
transcribed DNA strands that cause RNA polymerase to stall during transcription [99]. HIV has a
bias for integration inside actively transcribed genes. Therefore, it is likely that HIV integration
will cause arrest of transcription of the integration target genes [78, 81, 82]. Then, fact that
LEDGF/p75 interacts with SSRP1 will give an advantage to the virus to initiate efficient DNA
repair following viral DNA integration. Since LEDGF/p75 is a member of the elongation
complex it will be also advantageous for the virus the interaction with LEDGF/p75 to dock into
chromatin areas that are engaged in active transcription allowing efficient viral gene expression
rapid after viral integration.
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Chapter 7: Future Directions
Cellular levels of LEDGF/p75 and transcriptional regulation
Our data in Figure 10 indicate that there is a dramatic decrease of transcriptional activity
of the PARP9/DTX3L promoter when LEDGF/p75 is reexpressed. This inhibition was observed
in both promoter driven luciferase expression in HEK293 and cellular transcript levels in SupT1.
These results exclude the possibility that the generation of the cell lines was the cause of the
effect. A possibility exists that total cellular levels of LEDGF/p75 become rate limiting when
increased over a certain threshold. To compare levels of endogenous LEDGF/p75 to the
rexpressed we analyzed LEDGF/p75 transcript by qPCR in TC3, TL3 and TL3WT. To rexpress
LEDGF/p75 TL3 cells were transduced
with an MLV vector under the control of
a weak promoter to replicate endogenous
conditions.

The

rexpressed

proteins

contain a silent mutation to escape the
knockdown of endogenous LEDGF/p75
and primers were made against this
region to analyze by qPCR for the
detection of the rexpressed. Data in
Figure 18 indicates that levels of the

Figure 18. Transcript levels of re-expressed LEDGF/p75

LEDGF/p75 rexpressed transcript are Total mRNA was harvested and converted to cDNA via reverse
several

thousand

endogenous.

times

higher

transcriptase and subsequently measured by qPCR. Primers

than specific to the silent mutation allowing escape from endogenous

LEDGF/p75 knockdown were used to detect levels. IBD- cannot
be detected due to a lack of the target region in the transcript.
Results represent triplicate qPCR measurements.
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In both viral and cellular settings LEDGF/p75 has been demonstrated to be a tethering
molecule. It is plausible that this inhibition is caused by the binding of a cofactor of PARP9 and
DTX3L transcriptional activity. We can positively identify the region of LEDGF/p75 responsible
for the interaction in Figure 10. Here we demonstrate that a LEDGF/p75 lacking the IBD can
recover the transcriptional activity to normal levels. This suggests that LEDGF/p75 binds a
needed cofactor of the transcriptional apparatus and in overexpression systems can sequester it
causing inhibition. To analyze this we propose to use a TET inducible transduction system so
that induction of promoter activity can be titrated in TL3 cells. This should allow greater control
of LEDGF/p75 transcript levels and the ability to reduce them to endogenous levels. Should this
reagent demonstrate an ability to control the activity rate of the PARP9/DTX3L promoter it
would be valuable for the study of transcriptional regulatory role of LEDGF/p75 and the effect
of increased LEDGF/p75 production. We propose to use the PARP9/DTX3L promoter and
transcript detection methods characterized in this work for analysis of the inducible cell lines.
Further characterization of this cell line through chromatin binding strength, Integrase protection,
localization and infectivity assay could also yield new insights into HIV integration.
Alternative explanations for this inhibition include off target effect of the FLAG tag and
improper post translational modification of LEDGF/p75. The FLAG tag was included to
facilitate detection and immunoprecipitation. This tag is generally unobtrusive and was
extensively studied for effects on LEDGF/p75 function [93]. It was demonstrated to not have an
effect on the binding, localization, infectivity or Integrase protection activities of LEDGF/p75
but could possibly effect transcriptional regulation. LEDGF/p75 has been demonstrated to be
phosphorylated and sumoylated [93, 100]. If the mechanisms providing these changes to the
protein become overtaxed it could possibly lead to disruption of transcriptional activity. A study
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of the effect of LEDGF/p75 post translational modification effects on transcriptional regulation
is also proposed.

LEDGF/p75 post translational modification and transcriptional regulation
Our lab has identified two different post translational modifications of LEDGF/p75 [93,
100]. The first is a phosphorylation of serines 271, 273 and 275 by casein kinase 2. An
infectivity phenotype was established by conversion of these serines to alanines but no
corresponding reduction in the mutants’ capacity to bind to chromatin, protect Integrase or
localize to the nucleus was exhibited. The second is a series of Lysines determined to be
sumoylation targets of Sumo-1 and 3: K75, K250, K254 and K364. These sites were converted to
Arginines and determined to be of little effect in the context of viral infection, chromatin binding
and localization but demonstrated a longer protein half-life and an increased heat shock protein
27 promoter activity suggesting a limiting effect of the sumo sites on LEDGF/p75 transcriptional
activity. In this work we have established methods for studying LEDGF/p75’s effects on
transcript levels, promoter interaction, stress survival response, and interaction with the
transcription apparatus for the initiation and elongation steps. Investigating the mutants
abrogating these post translation modifications in these systems could potentially elucidate
LEDGF/p75 cellular mechanisms, yield new targets for drug intervention, or predict side effects
of interrupting LEDGF/p75 domain function.
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LEDGF/p75 mediated stress response in the transcriptome
The data from the microarray indicate that there is no significant modulation of stress
genes under basal conditions (Table 3). Yet a protective influence of LEDGF/p75 after cellular
stress responses can clearly be observed in Figure 6. Two possible hypotheses suggest
themselves from this ambiguity of cause in the presence of effect. The first is that under basal
conditions no LEDGF/p75 modulation of stress responding genes is detectable because the
activity is specific to the cell survival response and only detectable after cellular injury. The
alternative is that the cell survival phenotype is unrelated to the LEDGF/p75 transcriptional
regulatory activities implicating an as yet unknown cellular function. To test this we propose to
evaluate by qPCR the cellular stress gene subset presented in Table 3 after inducing osmotic and
oxidative stress to the cells. Clarifying this stress response would be of value to understanding
LEDGF/p75’s cellular role which is still largely disputed.

Drosophila model
There currently exist an animal model knockout of LEDGF/p75 in mouse and several
LEDGF/p75 depleted human cell lines [61, 77, 81]. Despite this there is an outstanding case for
developing a model in Drosophila melanogaster (Fruit Fly). The total protein encoding genes
from each species ~23,000 for Human and ~14,000 for the Fruit fly indicates that the fruit fly is a
simpler genome than the human. This is an advantage for use in determining potential
mechanistic functions of conserved proteins due to the number of cofactors possibly being less
numerous as well as overall less redundancy existing. This would allow researchers to more
definitively establish links to proposed functions and more clearly define its interactions. Or
more simply put, looking for a needle in a much smaller haystack. The second is ease of use. The
50

creation and maintenance of knockout flies are far simpler than that of mice allowing the rapid
development of LEDGF/p75 mutant progeny that can be evaluated for phenotype.
Any search for LEDGF/p75 homologs needs to account for the two primary domains:
PWWP and IBD. Of the genes in the HDGF family only LEDGF/p75 and HRP-2 contain these
domains. If it is assumed that this family of genes evolved from the same parent gene and the
lack of an IBD domain is a result of loss of function rather than an unlikely independent gain of
function in multiple species then a homolog would be limited to LEDGF/p75 and HRP-2
derivatives. An initial search of PFAM for all proteins containing a PWWP domain restricted to
Homo sapiens (Human) and Drosophila melanogaster returned 106 entries for human and 14
entries for fruit fly. Of these, two entries for human and one entry for fruit fly contained an IBD.
The two entries (LEDGF/p75 and HRP-2) for human confirm what was already known in the
literature lending confidence in the search.

Figure 19. Human and fruit fly entries that contain both the PWWP and IBD domains.

The empty bubble indicates the PWWP domain, the bubble labeled LEDGF denotes the IBD domain. Boxes are low
complexity areas. Diagram generated using PFAM.

Figure 19 depicts the entries in PFAM containing PWWP and IBD domains from Human
and Fruit Fly. In a closer inspection of the sequences between Human LEDGF/p75 and HRP-2 to
the Q9VAA9 using the EMBOSS Align tool available from EMBL there is little difference
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between LEDGF/p75 and HRP-2 alignments (Table 4). Again, there is no indication of which
gene this more closely resembles.
Table 5. Q9VAA9 alignments HRP-2 and LEDGF/p75.

Alignments made using EMBOSS align. Parameters for this analysis: Method – Water, Gap – 5.0, Extension – 0.5
and Matrix – Blosum62.
HRP-2

LEDGF/p75

Identity

19.9%

20.4%

Similarity

33.0%

36.0%

Gaps

38.6%

32.2%

Score

287.5

257.5

To investigate further which Human protein the Q9VAA9 sequence more closely
resembles a phospho site analysis using Scansite from MIT. Noting the difference in both serine
count and phospho site prediction between LEDGF/p75 and HRP-2 we can see in table 5 that in
this characteristic a much clearer similarity of Q9VAA9 to LEDGF/p75. The analysis uses only
one prediction software; it is not comprehensive but is suggestive that the function of this protein
may be more similar to that of LEDGF/p75.
Table 6. Q9VAA9 phospho site prediction.

Percentage of Serines calculated using total serines / total amino acids. Kinase groups listed using nomenclature
from Scansite: Baso_ST_Kin – Basophilic Serine/Threonine Kinase, Kin_Bind – Kinase binding group,
Acid_ST_Kin – Acidophilic Serine/Threonine Kinase group, DNA_DAM_Kin – DNA damage Kinase group, SH3 –
Src Homology Group 3.

Length
Serines
Phospho sites

HRP-2

LEDGF/p75

Q9VAA9

671
82 (12.22%)
7 sites
SH3
Acid_ST_Kin Baso_ST_Kin

540
35 (6.48%)
4 sites
Acid_ST_Kin Baso_ST_Kin
DNA_DAM_Kin

475
27 (5.68%)
2 sites
Baso_ST_Kin
Kin_bind
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There is a paucity of HRP-2 gene regulatory information available so presented here are
suggested regulatory targets of LEDGF/p75 only. Table 3 depicts where information available
through NCBI: Blast, Pubmed, Entrez, Homologene or Sanger: PFAM for a potential homolog in
Fruit Fly could be found. A confirmed status indicates there are primary literature entries for
Drosophila. Suggested homolog indicates which gene has an alignment indicating a possible
homolog. In many cases a specific homolog has not been defined but the gene family it belongs
to is present and may provide an interesting target.
For environmental stress related genes reported to be influenced by LEDGF/p75, Hsp70
is confirmed and Hsp20 family is present. Potential homologs for Alpha B Crystallin and
Antioxidant Protein 2A are also present. Of the genes influenced by the Menin/MLL interaction
with LEDGF/p75 Homeobox A7 and Meis1 are confirmed and a suggested homolog for the
Cyclin-dependent kinase inhibitor 1b is present. Of the targets found in the microarray analysis
there are two confirmed: DTX3L and RORB. As well two potential targets in PARP and
phosphodiesterase protein family are present. A lack of information does not imply that the gene
does not exist in the Fruit Fly but rather that to date there is nothing in the literature linking them.
There are enough homologs and potential homologs to study Q9VAA9 functional similarities to
LEDGF/p75 in gene regulation. In conclusion, our hypothesis is that Q9VAA9 is a LEDGF/p75
homolog and that D.melanogaster would make an excellent model system to study LEDGF/p75
cellular function.
A fly Q9VAA9 knockout animal has been generated but not characterized yet. It will be
very informative to determine the susceptibility of this mutant to environmental stresses.
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Table 7. Drosophila homologs.

Results obtained using NCBI: Pubmed, Entrez, Homologene and Blast as well as Sanger: PFAM. Status results
indicate Confirmed: Primary Literature entries for Drosophila, Homolog: Sequence similarity, Family members
present: Weak correlation but potential target.

Name
Involucrin
Alpha B Crystallin
Heat Shock Protein 27

Source of Interaction
Environmental Stress
Environmental Stress
Environmental Stress

Heat Shock Protein 70 family
Antioxidant Protein 2
Homeobox A6
Homeobox A7
Homeobox A9
Meis 1
Cyclin-dependent kinase Inhibitor 2C
Cyclin-dependent kinase Inhibitor 1B

Environmental Stress
Environmental Stress
MLL/Menin
MLL/Menin
MLL/Menin
MLL/Menin
MLL/Menin
MLL/Menin

ATP Binding Cassette A1
Deltex 3-Like
Parp 9
Ecotropic viral integration site 21
gap junction protein, β2
glutamine-fructose-6-phosphatetransaminase
phosphodiesterase 9a

Microarray
Microarray
Microarray
Microarray
Microarray
Microarray

rar-related orphan receptor b

Microarray

Microarray
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Status in Drosophila
Suggested Homolog: l(2)efl
HSP 20 family members
present
Confirmed
Suggested Homolog: Prx6005
Confirmed
Confirmed
Suggested Homolog:
P91668_DROME
Confirmed
Parp family members present
Phosphodiesterase family
members present
Confirmed

Chapter 8: Supplemental Figures
A – DTX3L/PARP9 Promoter experiments
A

B

C

D

Figure 20 DTX3L/PARP9 Promoter experiments

E

A) IFNγ titration. The results are shown in relative light units
corrected for the loading control β-Galactosidase. Samples were
either treated with 0 to 5kU IFNγ 24 hrs after transfection with
500ng DTX3L promoter. No LEDGF/p75 was added. B) PARP9
with and without IFNγ . The results are shown in relative light
units corrected for the loading control β-Galactosidase. Samples
were either treated with 0 or 150 U IFNγ 24 hrs after transfection.
LEDGF/p75, p52 or an empty plasmid control were added where
indicated. 500ng of DTX3L promoter added C) LEDGF/p75
Titration. The results are shown in relative light units corrected
for the loading control β-Galactosidase. Samples were either
treated with 0 to 600ng LEDGF/p75 and 500ng DTX3L promoter
in the presence of 150 U IFNγ. D) Timecourse. The results are
shown in relative light units corrected for the loading control βGalactosidase. Samples were either treated with 75 or 150 U IFNγ,
250 ng of LEDGF/p75 and 500ng of DTX3L promoter. Cells were
harvested either 24 or 36 hours post transfection. E) DTX3L
Titration. The results are shown in relative light units corrected
for the loading control β-Galactosidase. Samples were either
treated with 250 to 1000ng of DTX3L and 250ng of LEDGF/p75 ,
150 U IFNγ LEDGF/p75 and 500ng DTX3L promoter in the
presence of 150 U IFNγ
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B – Real-Time PCR Primers
ChIP
Gene

ID

Forward

ID

Reverse

ABCA1
Promoter

JK48

CCACTGGTGCCCTTGGCTGC

JK49

AGCAGGTGTCTTAGGGTCCGC

Exon

JK30

AGCTCCAGCTCCTCCACCCA

JK31

GCCATTGCCTCCAAAGAGGGC

EVI2A
Exon

JK32

GCCATTGCCTCCAAAGAGGGC

JK33

AGGTTGGGTCCTGTGAGCTGT

Promoter

JK50

TGGAGGCAACGGATGCGGAG

JK51

GACTGTAAAGCCCCAAAGGTCAGC
C

Exon

JK34

CACACCAATCGCGTCATCTTTCT
GG

JK35

TTTGCACAGCTCGTCCGGGG

GJB2
Exon

JK36

GGTCCGCATCGAAGGCTCCC

JK37

CCGCTGCATGGAGAAGCCGT

Promoter

JK11

AGTGGCGGCGTAAATCCT

JK12

Exon

JK38

CCGCTGCATGGAGAAGCCGT

JK39

TGATCACGTCTGTGGCTTATTTGA
A
TTCCTCACTGTTCGTCTGGTGCAA

GGCAGCTGGGCGGTAAAGGC

JK25

GCAGGAGAGGGGACCCCGAG

GCCCGGGCTGACCTCATTG

JK27

GAGCGCCAAAGGCCTCGCTC

GFPT1

HOXA9

PARP9

Exon

JK24
a
JK26

PDE9A
Exon

JK40

AGAGCTGGCGGTCCGCTACA

JK41

TGTTGCACTCAGGCTCGGCG

JK42

TGTTGCACTCAGGCTCGGCG

JK43

GCCCGTTGGCATAAGTGCCG

Exon

JK44

TCACAAGCTGCGTCAAGGTGAG
A

JK45

TGTCCGTCTTGTCTTCAGAGAAGG
GA

UNTR
Control

JK28

GCAGCAGGGGCTGGCCTTTT

JK29

GCCCTAGGTCTAACAGGAGCCACC

ID

Forward

ID

Reverse

Control
PARP9

JK9

CCCCTCCTAGGCCTTTGC

JK10

GCTGAGAGGCGGGAAAGTT

Transcript
DTX3L

JK16

CAATGGTCGTGAACAACCTG

JK17

CAACTGGGACCGTTGAAACT

Transcript

JK18

GAGTTCAGTGAAAGGGCAGC

JK19

TGCATATCACCAGACGGTGT

Promoter

RORB
Exon
TAX1BP
3

mRNA
Gene
GAPDH
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C – ChIP Protocol
Adapted from the ROCHE/NimbleGen ChIP on Chip protocol for use with SupT1 derived cell lines.
Day 1
Cross-linking
Bead Prep
Day 2
Buffer Prep
ChIP reactions
Day 3
Wash & Elute
Day 4
Purification
Amplification
! Buffers listed here can be premade and aliquoted or stored at 4C. Buffers listed within the protocol should be made directly
prior to use. This is especially important for the Elution Buffer.
Stock solution prep
1. Glycine (Sterile Prep) 2.5M
a. Add 1.88g of Glycine to 10ml H2O
b. Vortex until dissolved
c. Autoclave
2. 0.5M EDTA, pH 8.0
a. Adjust pH of EDTA to 8.0
b. Autoclave
3. 0.5M EGTA, pH 8.0
a. Add .95g to 2.5 ml of H2O
b. Adjust pH to 8.0
c. Bring to 5mls TV
d. Autoclave
4. 1M Tris, pH8.0
a. Adjust pH of Tris 1M to 8.0
b. Autoclave
5. 1M HEPES pH8.0
a. Add 250ul of 1M HEPES to 4.75ml of H2O
b. Adjust pH to 8.0
6. 1M HEPES KOH pH7.5
7. 80% glycerol stock, 5ml
a. Add 4ml of Glycerol to 1ml of H2O
8. 10% Triton x-100 stock
a. Add 500ul of Triton 100% to 4.5ml of H2O
9. TE 10x pH 8.0
a. EDTA, 0.5M
100mM
b. Tris HCL, 1M
10mM
c. Bring volume to 5ml with H2O
d. Adjust pH to 8.0
e. Autoclave
10. TE 1x pH.0
a. 10x TE
b. H2O
11. Prepare 10mls 1x PBS
a. 10x PBS
b. H2O
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– 10ml

– 5ml
– 5ml

– 4ml
– 4ml
– 5ml

– 1000ul
– 50ul

– 1ml
– 9ml
– 1ml
– 9ml

Day 1
Cross-linking
1. Prepare 1ml Cross-linking solution
a. Formaldehyde, 37%
11% v/v
b. NaCl, 5M
0.1M
c. EDTA pH 8.0, 0.5M
1mM
d. EGTA pH 8.0, 0.5M
0.5mM
e. Hepes, pH8.0, 1M
50mM
f. H2O
2. Harvest 15x106 cells LSS-BC-WT
3. Spin @ 1600 for 6’
4. Re-suspend in 700ul of Media
5. Add 70ul of cross-linking solution
6. Incubate on ice for 10’
7. Add 38.5ul of Glycine solution.
8. Spin @ 2000g for 10’ at 4C
9. Decant super
10. Wash 2x
a. Resuspend in 1ml ice cold PBS
b. Spin @ 2000g for 10’ at 4C
c. Decant super
11. Snap Freeze pellet in Liquid Nitrogen and store at -80C

– 297ul
– 20ul
– 2ul
– 1ul
– 50ul
– 630ul

Bead Preparation
1. BSA Blocking solution 20mls
a. BSA
– 0.1g
b. PBS 1x
– 20mls
2. Put 50ul of Sheep anti-mouse Dynabeads into a 1.5ml tube – Mix Gently *This will depend on anti-body type
3. Spin @ 2000g for 5’ at 4C
4. Decant super with pipette
5. Blocking solution wash x 3
a. Resuspend in 1ml of blocking solution
b. Magnetic bead capture
c. Decant super
6. Resuspend in 300ul of blocking solution
7. Add 3ug of anti-Flag (3ul anti-Flag) * Will depend on anti-body used
8. Incubate overnight at 4C on the rotary wheel.
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Day 2
Buffer Preparation
1. Lysis Buffer (L1) 5mls –
a.
Hepes KOH, pH 7.5, 1M
50mM
– 250ul
b. NaCl, 5M
140mM
– 140ul
c.
EDTA, 0.5M
1mM
– 10ul
d. Glycerol, 80%
10%
– 625ul
e.
NP-40, 10%
0.5%
– 250ul
f.
Triton x-100, 10%
0.25%
– 125ul
g. Protease Inh.
– 20ul
h. H2O
– 3.58ml
2. Buffer (L2) 5ml
a.
NaCl, 5M
200mM
– 200ul
b. EDTA pH8.0, 0.5M
1mM
– 10ul
c.
EGTA pH8.0, 0.5M
0.5mM
– 5ul
d. Tris pH8.0, 1M
10mM
– 50ul
e.
Protease Inh.
– 20ul
f.
H2O
– 4.71ml
3. Buffer (L3) 2ml * Make more than the minimum
a.
EDTA pH8.0, 0.5M
1mM
– 4ul
b. EGTA pH8.0, 0.5M
0.5mM
– 2ul
c.
Tris pH8.0, 1M
10mM
– 20ul
d. Protease Inh.
– 8ul
e.
H2O
– 1.966ml
4. Thaw pellet in ICE WATER slushee for 1hr.
5. Resuspend pellet in 1.2ml of L1.
6. Incubate on rotary wheel in 4C for 10’
7. Spin @ 14k rpm at 4C for 5’
8. Decant super
9. Resuspend pellet in 1ml of L2
10. Incubate on rotary wheel in 4C for 10’
11. Spin @ 14k rpm at 4C for 5’
12. Decant super
13. Resuspend pellet in 500ul of L3
14. Sonicate: Microtip, amp: 20%, 20”, rest on ice 30” x 13. Sonicate more if cloudy.
15. Spin @ 4000rpm at 4C for 15’
16. Move super to new tube.
17. Measure DNA concentration on Nanodrop, run on gel * Careful here
18. Add 70ul of 80% glycerol stock
19. Adjust concentration to 2mg/ml by precipitation or dilution with L3
20. Make one 25ul aliquot, make Total 40ul+8ul 6x laemli / boil, remaining to a 1.5ml tube *To test sonication conditions you can run
the 10ul Total in a 1% agarose gel. Be sure to complete the de-crosslinking process prior to running the sample or it will run
high. The majority of the fragments should be between 200 and 1000bp.
21. Freeze chromatin samples at -80C
ChIP reactions
1. 10% deoxycholate 3mls
a.
Deoxycholate
b. H2O
2. BSA Blocking solution 20mls
a.
BSA
b. PBS 1x
3. Magnetic bead capture of antibody/beads
4. Decant super
5. Wash x 3
a.
Resuspend in 500ul of PBS 1x
b. Magnetic bead capture
c.
Decant super
6. Resuspend pellet in 30ul of BSA blocking solution
7. Thaw chromatin sample.
8. Prepare IP reaction
a.
Chromatin sample
b. Triton x-100, 10%
1%
c.
Deoxycholate, 10%
0.1%
d. Protease Inh
e.
TE 10x
1x
f.
Dynabead complex
9. Incubate on rotary wheel at 4C overnight.

– 0.3g
– 3ml
– 0.1g
– 20mls

– 202.3ul
– 30.2ul
– 13ul
– 4ul
– 30.5ul
– 30ul
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Day 3
Buffer Preparation
1. RIPA buffer
a. Hepes, pH 8.0, 1M 50mM
b. EDTA pH8.0, 0.5M
c. NP-40, 10%
d. Deoxycholate, 10%
e. H2O
f. LiCl, 8M
g. Protease Inh.
2. Elution buffer 5 mls
a. Tris pH8.0, 1M
b. EDTA pH 8.0, 0.5M
c. SDS, 10%
d. H2O
3.
4.
5.

6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.

5 mls
– 250ul
– 10ul
– 500ul
– 350ul
– 3.55ml
– 312.5ul
– 20ul

1mM
1%
0.7%
0.5M
10mM
1mM
1%

– 100ul
– 20ul
– 1ml
– 8.87ml

Magnetic Bead Capture
Save the supernatant @ -80C (NB Fraction) 20ul +4ul 6x laemli
Wash x 8
a. Resuspend Beads in 500ul of RIPA
b. Magnetic Bead Capture
c. Discard super
Resuspend beads in 500ul of TE 1x
Move to a sterile 1.5ml tube
Magnetic Bead Capture
Discard Super
Spin @ 3000rpm for 3’
Discard remaining super
Add 50ul of elution buffer
Vortex
Incubate beads at 65C for 10’, vortex every 2’
Spin @ TS for 30s
Move super to a clean tube
Add 120ul of elution buffer.

18. Thaw Total Fraction
19. Add 145ul of Elution Buffer
20. Transfer all samples to 65C heatblock, incubate ON
Day 4
Post IP cleanup
1. Add 5.6ul RNase 10mg/ml to bound sample.
2. Incubate for 2hrs at 37C waterbath
3. Proteinase K Mix
a. TE 1x
– 143ul
b. Proteinase K 20mg/ml
– 7ul
4. Add 150ul of proteinase K solution
5. Vortex lightly
6. Incubate at 37C for 2 hours
7. Purify DNA using Qiaquick PCR cleanup kit
8. Elute in 30ul
9. Nanodrop Spectrophotometry for input controls
10. Store all samples at -20C
Samples ready for QPCR.
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Terms and Usage
ABCA1
ATP
BAL1
BBAP
BBRC
BET
BRD(4)
CBD
CD(4+)
CDC:ASK
CDK(9)
CDKN(2C)
ChIP
CMV
COMPASS
CpG Island

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

CSB
CSK(I,II)
DAVID

–
–
–

DELTEX (3)

–

DLBCL
DMEM
(c)DNA
DRB
DSIF
DTT
EDTA
eGFP
ELL
EVI(2A)
FACT
FLAG
G418
GAPDH
GFPT1
H2O2
HEK293

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

ATP-binding cassette, sub-family A, Member 1.
Adenosine triphosphate.
B-aggressive lymphoma 1, Gene for PARP9.
deltex 3-like (Drosophila).
Border Biomedical Research Center.
Bromodomain and ET domain.
Bromodomain containing, Member 4.
Chromatin binding domain.
Cluster of differentiation, Member 4 activated.
Cell cycle related, Member aspartate kinase.
Cyclin-dependent kinase, Member 9.
Cyclin-dependent kinase inhibitor, Member 2C.
Chromatin immunoprecipitation.
Cytomegalovirus promoter.
Complex Proteins Associated with Set1.
Regions that contain a high frequency of Cytosine Guanine
dinucleotides bound by a phospodiester bond.
CS group B correcting gene, excision repair.
Isotonic salt buffers, type 1 and 2.
Database for Annotation, Visualization and Integrated Discovery
v6.7.
Members of the DELTEX family act as Notch signaling modifiers and
may also regulate transcription.
Diffuse large b-cell lymphoma.
Dulbecco's modified eagle medium.
Deoxyribonucleic Acid, c - complementary DNA.
MHC class II DR-beta chain.
DRB sensitivity-inducing factor.
Dithiothreitol.
Ethylenediaminetetraacetic acid.
Enhanced green flourescent protein.
Elongin and Eleven-nineteen lysine rich in leukemia.
Ecotropic viral integration site, member 2A.
Facilitates chromatin transcription.
Polypeptide protein tag.
Selection antibiotic.
Glyceraldehyde-3-phosphate dehydrogenase.
Glutamine--fructose-6-phosphate transaminase, member 1.
Hydrogen Peroxide.
Embryonic kidney epithelial cells.
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HeLa
HHMI
HIV(-1,-2)
HOX(A6,A7,A9)
HSE
IBD
IFN(γ)
IN
Jurkat
kB
mAbs
MCM2
Meis(1)
MgCl2
Myc
NaCl
NCBI
NELF
NH4SO4
NIGMS
NIH
p1012
PA-

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

pAbs
PAF
PARP(9)
PBS
(q, qRT)PCR

–
–
–
–
–

PDE(9A)
pEFIRES
pGL3
PIC
PMSF
POLII
PSIP1
P-TEFb

–
–
–
–
–
–
–
–

PWWP

–

RBP(1,2)
(sh, m)RNA

–
–

Cervical cancer cells taken from Henrietta Lacks.
Howard Hughes Medical Institute.
Human immunodeficiency virus, Members 1 and 2.
Homeobox, Members A6, A7, and A9.
Heat shock element.
Integrase binding domain.
Interferon gamma.
HIV-1 Integrase.
CD4+ T cells.
One thousand bases.
Monoclonal antibodies.
Minichromosome maintenance complex component, member 2.
Myeloid ecotropic viral integration, member 1.
Magnesium Chloride.
DNA binding factor involved in transcription.
Sodium Chloride.
National Center for Biotechnology Information
Nasal embryonic LHRH factor.
Ammonium Sulfate.
National Institute of General Medical Sciences.
National Institutes of Health.
Expression plasmid.
LEDGF/p75 mutants rexpressed lacking the PWWP and AT Hook
domains.
Polyclonal antibodies.
Pol II Associated Factor.
Poly-(ADP-ribose) polymerase, Member 9.
Phosphate buffered saline.
Polymerase chain reaction, q - quantitative, qRT - quantitative
reverse transcriptase.
Phosphodiesterase, Member 9A.
Expression plasmid.
Expression plasmid.
Preintegration complex.
Phenylmethanesulfonylfluoride or phenylmethylsulfonyl fluoride.
RNA polymerase II.
PC4 and SFRS1 interacting protein 1.
Positive transcription elongation factor b, contains to subunits
Cyclin T and CDK9.
Proline Tryptophan Tryptophan Proline motif part of the
LEDGF/p75 chromatin binding domain.
RNA binding protein, Members 1 and 2.
Ribonucleic Acid, m - messenger, sh - short hairpin.
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RORB
RPMI
SPT(5, 16)
SSRP(1)
STRE
SupT1
TAX1BP(3)
TBP
TC-NER
TFII(D, H, F, S)

–
–
–
–
–
–
–
–
–
–

THO/TREX

–

UTEP
VEGF(-C)
WT
XPG

–
–
–
–

RAR-related orphan receptor B.
Roswell Park Memorial Institute Medium.
SPT Transcription Elongation Family, Members 5 and 16.
Structure specific recognition protein, Member 1.
Stress response element.
CD4+ T cells.
Human T-cell leukemia virus type I binding protein, Member 3.
TATA binding protein (aka. TFIID).
Transcription coupled nucleotide excision repair.
Transcription Factor II, D - TATA binding protein (aka. TBP), H - ,
F -, S-.
Conserved eukaryotic complex involved in mRNA metabolism and
export.
University of Texas at El Paso.
Vascular Endothelial Growth Factor, Member C
Wildtype.
Structure specific DNA endonuclease.
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